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Breast cancer is one of the most common cancers in the world. The advancement in 
diagnostic tools and treatment options have majorly improved the prognosis of the 
disease. Nevertheless, every year thousands of women receive this diagnosis and 
undergo breast cancer surgery in hope of survival. 
Modern	 day	 surgery	 requires	 efficient	 analgesia	 to	 protect	 the	 body	 from	 the	
stress caused by severe pain. Therefore, analgesics are used both intra- and post-
operatively. Opioids are the gold standard analgesic for moderate or severe post-
operative pain and oxycodone has been the opioid most used for post-operative 
pain	in	Finland	for	decades.	Due	to	the	serious	adverse	effects,	all	opioids	must	
be titrated to analgesic doses gradually, which prolongs the time it takes to reach 
satisfactory	 analgesia	 and	 predisposes	 patient	 to	 suffering	 and	 to	 the	 harmful	
physical	 effects	 of	 pain.	 The	 purpose	 of	 this	 thesis	 was	 to	 identify	 whether	
oxycodone	has	an	analgesic	plasma	concentration,	as	well	as	which	factors	affect	
the post-operative pain intensity and oxycodone requirements after breast cancer 
surgery.	The	 identification	of	 these	 factors	helps	clinicians	 recognize	patients	at	
risk of severe post-operative pain and in need of higher doses of oxycodone to 
reach satisfactory analgesia. 
The study cohort consisted of 1,000 women about to undergo breast cancer 
surgery due to unilateral non-metastasised breast cancer. Before the surgery, 
each patient`s demographic data, medical history, pain, depressive symptoms 
and anxiety state were recorded along with heat (48°C) and cold (4°C) pain 
sensitivity. Anaesthesia protocol was standardized. After the surgery, all patients 
were titrated to satisfactory analgesia with intravenous oxycodone. The post-
operative pain intensities and oxycodone requirements were recorded from the 
first	20	post-operative	hours.	
Post-operative pain intensity, requirement of oxycodone and analgesic oxycodone 
concentrations	varied	significantly	between	patients.	Factors	associated	with	higher	
post-operative motion pain were young age, axillary clearance (vs. sentinel node 
biopsy), higher preoperative cold pain intensity and cold pain tolerance. Together 
these factors explained 8.5% of the variation in the motion pain intensities. 
Post-operative motion pain intensity was the major predictor of post-operative 
oxycodone requirement, together with BMI, age, axillary clearance, OPRM1 
rs1799971 genotype and preoperative breast pain. Together these factors explained 
28% of the total variation in oxycodone requirement. Only post-operative motion 
pain intensity and axillary clearance were associated with analgesic oxycodone 
plasma concentrations, which together explained almost 17% of the total variation. 
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CYP2D6 genotype did not associate with the analgesic oxycodone requirement 
or	 concentration	 but	 did	 affect	 the	 oxymorphone	 and	 noroxymorphone	 plasma	
concentrations.
The results presented in this study could help identify patients at risk of higher pain 




Rintasyöpä on yksi mailman yleisimmistä syövistä. Diagnostiikan ja hoitokeinojen 
kehittyminen on merkittävästi parantunut taudin ennustetta. Kuitenkin joka vuosi 
tuhannet naiset saavat rintasyöpädiagnoosin ja läpikäyvät rintasyöpäleikkauksen toi-
voen parantumista. 
Nykyaikainen kirurginen hoito vaatii tehokasta kivunlievitystä, sillä voimakas kipu 
altistaa elimistön merkittävälle rasitukselle. Kivun lievittämiseksi leikkauksen ai-
kana ja sen jälkeen potilaalle annostellaan kipulääkkeitä, joista opioidit ovat käyte-
tyin kipulääkeryhmä keskivaikean ja vaikean leikkauksen jälkeisen kivun hoidossa. 
Opioidihoitoon liittyy kuitenkin vakavia haittavaikutuksia, kuten pahoinvointi ja 
hengityslama, joiden vuoksi kaikki opioidit joudutaan titraamaan kipua lievittävään 
annokseen asteittain. Tämä pitkittää riittävän kivunlievityksen saavuttamiseen ku-
luvaa aikaa ja altistaa potilaan kivun aiheuttamalle kärsimykselle ja elimistön kuor-
mitukselle. Oksikodoni on ollut vuosikausia Suomen käytetyin opioidi leikkauksen 
jälkeisen kivun hoidossa. Tämän väitöskirjan tarkoitus oli tutkia, onko oksikodonille 
määritettävissä analgeettista pitoisuutta sekä määrittää leikkauksen jälkeisen kivun 
voimakkuuteen ja oksikodonin tarpeeseen vaikuttavia tekijöitä. Näiden tekijöiden 
tunnistaminen helpottaisi riskipotilaiden tunnistamista sekä voimakkaan leikkauk-
sen jälkeisen kivun että suuren oksikodonin tarpeen suhteen. Näin hoitohenkilökunta 
voisi jo ennalta varautua haastavaan postoperatiivisen kivun lievitykseen. 
Tutkimuspopulaatio koostui 1000 naisesta, jotka olivat menossa rintaleikkaukseen 
diagnosoidun rintasyövän vuoksi. Potilailla oli vain toisen rinnan tauti eikä heillä ol-
lut	havaittu	etäpesäkkeitä.	Ennen	leikkausta	potilaat	täyttivät	kyselyt	demografisista	
tiedoistaan, sairaushistoriastaan, kipuoireistaan sekä masennus- ja ahdistustasostaan. 
Lisäksi potilaiden herkkyys kokeelliseessa kuuma- ja kylmä-kipukokeessa sekä kyl-
mäkivun sieto testattiin. Tutkimuspotilaiden anestesia oli vakioitu. Leikkauksen jäl-
keen kaikkille potilaille annosteltiin suonensisäistä oksikodonia kunnes he ilmai-
sivat kivunlievityksen olevan riittävä. Leikkauksen jälkeinen kivun voimakkuus ja 
oksikodonin käyttö kirjattiin ensimmäisen 20 leikkauksen jälkeisen tunnin ajalta. 
Hyvään kivunlievitykseen tarvittavat plasman oksikodonipitoisuuden vaihtelivat huo-
mattavasti potilaiden kesken. Leikkauksen jälkeiseen liikekivun voimakkuuteen liit-
tyvät tekijät olivat nuori ikä, kainalon imusolmukkeiden poisto (vs. vartijaimusolmu-
kebiopsia), suurempi herkkyys kylmäkivulle ja vähäisempi kylmäkivun sieto. Nämä 
tekijät selittivät yhteensä 8,5 % leikkauksen jälkeisen liikekivun voimakkuudesta. 
Lekkauksen jälkeinen liikekivun voimakkuus puolestaan liittyi vahvasti leikkauksen 
jälkeiseen oksikodonin kulutukseen samoin kuin painoindeksi, ikä, kainalon imusol-
mukkeiden poisto, OPRM1 genotyyppi ja leikkausta edeltänyt kipu rinnassa. Nämä 
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tekijät selittivät jopa 28 % oksikodonin tarpeen kokonaisvaihtelusta. Vain leikkauksen 
jälkeinen liikekivun voimakkuus ja kainalon imusolmukkeiden poisto liittyivät oksi-
kodonin analgeettiseen plasmapitoisuuteen. Yhdessä ne selittivät 17 % tämän vaihte-
lusta. CYP2D6 genotyyppi ei vaikuttanut leikkauksen jälkeiseen oksikodonitarpeeseen 
tai analgeettiseen plasmapitoisuuteen, mutta se vaikutti leikkauksen jälkeisiin oksiko-
donin metaboliittien oksimorfonin ja noroksimorfonin plasman pitoisuuksiin. 
Väitöskirjan tulokset auttavat tunnistamaan rintasyöpäleikkauksen läpikäyneitä po-





Opioids, including oxycodone, are widely used for acute post-operative pain. 
However, their administration is often complicated by the extensive variations in 
therapeutic range of these drugs. Due to highly individual dosage requirements, 
opioids must be slowly titrated to analgesic plasma concentrations thus delaying 
satisfactory analgesia. In order to hasten the achievement of satisfactory analgesia it 
is critical to have tools to predict the patient’s oxycodone requirement. Many studies 
have found clinical factors that act as such predictors, for example preoperative 
anxiety,	 age	 and	 preoperative	 chronic	 pain.	 (Ip	 et	 al.,	 2009).	 Different	 types	 of	
surgery	 predispose	 patients	 to	 different	 post-operative	 pain	 intensities	 and	 opioid	
requirements according to the invasiveness of surgery and the tissues operated. (Ip et 
al., 2009; Chiang et al., 2016). 
Most studies have used opioid consumption as a proxy for post-operative pain and 
its	 relief,	 although	many	 factors	 interfere	with	 the	 administered	 dose	 and	 the	 final	
central nervous system (CNS) concentration. One of these factors is the metabolism 
of oxycodone by the cytochrome P450 enzyme family. The major metabolic routes of 
oxycodone involve CYP3A4/5, which metabolises oxycodone to noroxycodone and 
CYP2D6, which in turn produces oxymorphone. The activity of these two enzymes 
could	 significantly	 alter	 the	 amount	 of	 oxycodone	 reaching	 the	CNS	and	 therefore	
the	effect	oxycodone	analgesia.	The	activity	of	CYP2D6	is	greatly	affected	by	genetic	
variants,	for	example,	in	some	individuals,	the	enzyme	is	totally	ineffective	whereas	
in others the enzyme activity is greatly increased. CYP3A4/5 is the major metaboliser 
of many clinically used drugs and as a result, the function of the enzymatic pathway is 
susceptible to both interactions with other drugs as well as genetic variation.
The	desired	pharmacodynamic	effects	of	opioids	take	place	in	opioid	receptors	 in	
the CNS. Thus, to achieve the most accurate depiction of opioid requirements, the 
patient’s oxycodone concentration should be measured directly from the CSF. The 
invasiveness	 of	 the	 CSF	 collection	 and	 the	 possible	 side	 effects	 (e.g.	 headache)	
make the study of CSF concentrations both costly and hard to execute. However, 
even	CSF	concentrations	cannot	fully	reflect	the	concentrations	at	the	site	of	action,	
since opioid receptors are widely scattered around the CNS and peripheral nervous 
system. So far, to the best of the author’s knowledge, only one previous study 
has	measured	 the	 analgesic	 cerebrospinal	 fluid	 oxycodone	 concentrations	 (Kokki	
et al., 2014). Nonetheless, a few studies have investigated the analgesic plasma 
oxycodone concentrations and the factors predicting analgesic oxycodone plasma 
concentrations.	Of	which,	 three	studies	have	aimed	 to	find	a	 therapeutic	 range	of	
plasma oxycodone in laparoscopic cholecystectomy (Piirainen et al., 2015; Kokki et 




on genetics. In the studies of this thesis, we have focused on the genes potentially 
affecting	 experimental	 and	 postoperative	 pain	 intensity	 as	 well	 as	 oxycodone	
analgesia: OPRM1, FAAH, CYP2D6 and CYP3A4/5. 
OPRM1	codes	for	the	mu	opioid	receptor	that	is	partly	responsible	for	the	CNS	effects	
(analgesia, drowsiness etc.) of opioids together with kappa and delta receptors. The 
opioid system is also highly involved in the regulation of anxiety (Colasanti et al., 
2011) and blocking the opioid receptors by naloxone has been shown to increase the 
self-rated anxiety in a dose dependent manner (Pickar et al, 1982). In the OPRM1 
gene, a single nucleotide polymorphism (SNP) is of special interest since it leads 
to an amino acid substitution from aspartate to asparagine, therefore changing 
the	N-glycosylation	 of	 the	mu	 receptor	 protein	 (Huang	 et	 al.,	 2012).	The	 effects	
of this rs1799971 polymorphism have been studied with regard to both exo- and 
endogenous opioids. The amino acid substitution alters the binding potential of the 
receptor	for	endogenous	opioid	β-endorphin	and	possibly	to	other	opioids	as	well	
(Bond et al., 1998). In addition, it has also been shown to decrease the receptor’s 
stability	in	mice	(Huang	et	al.,	2012).	Other	studies	that	have	focussed	on	the	effects	
of rs1799971 polymorphism on opioid analgesia have mainly used morphine as their 
drug of choice, although so far the results have been inconclusive, whereas studies 
devoted to rs1799971 and oxycodone analgesia are rare. 
FAAH codes for fatty acid amide hydrolase, a protein degrading endogenous 
cannabinoids in both the CNS and periphery. The enzyme can degrade many 
substrates including the main endocannabinoid anandamide (AEA), which is released 
to the synaptic cleft, where it binds to CB1 and CB2 receptors and is then internalized 
to the neuron. Intracellular FAAH inactivates AEA by breaking it into arachidonic 
acid and ethanolamine. 
Since	FAAH	activity	affects	the	AEA	concentration	and	thus	the	endocannabinoid-
mediated analgesia, it is an interesting object to study from both a pharmacogenetic 
and pharmacological aspects. Endocannabinoids have also been shown to participate 
in the regulation of anxiety in animal and human models (Dincheva et al., 2015; 
Viveros et al., 2005; Moreira et al., 2008).
The	overall	aim	of	this	thesis	was	to	find	whether	there	is	an	analgesic	oxycodone	
concentration and to determine more precise, predictive factors to estimate the 
oxycodone	doses	needed	for	satisfactory	post-operative	analgesia.	More	specifically,	
the aim was to clarify the roles of important clinical variables, OPRM1 rs1799971 and 




2. REVIEW OF LITERATURE
2.1 Pain
According to the International Association for the Study of Pain, pain is “an 
unpleasant sensory and emotional experience associated with actual or potential 
tissue damage, or described in terms of such damage” (IASP Taxonomy 2018). Pain 
is not only a vital protective signal to prevent tissue damage but a stimulus to teach 
the avoidance of harmful behaviour. Pain can be categorized in many ways; based 
on	duration,	pain	can	be	defined	as	acute	(less	than	6	weeks),	subacute	(6	weeks	to	
3 months) or chronic (more than 3 months). The type of pain can be categorized as 
nociceptive,	neuropathic	or	inflammatory.	Several	other	classification	methods	exist	
and even more ways are used to describe the sensation pain causes. Nevertheless, 
pain is always a subjective experience and for instance, individuals report highly 
variable pain scores even when the nociceptive stimulus has been standardized 
(Coghill et al., 2003). The sensation caused by a nociceptive stimulus is a complex 
phenomenon,	which	is	affected	by	many	biological	and	psychological	factors.
2.1.1 From nociception to pain
The human body can detect many somatosensory stimuli such as touch, vibration, 
temperature, proprioception and nociception. Nociception is the peripheral nervous 
system’s response to certain harmful or potentially harmful stimuli, which is usually 
experienced as pain. The pain experience generally starts with the activation of 
a peripheral nerve ending called the nociceptor. Nociceptors can be activated by 
multiple factors such as temperature, pressure and chemical agents. A stimulus strong 
enough in intensity causes the cation channels on a nociceptor to open, and the cell 
membrane depolarizes. If a threshold potential is achieved, an action potential is 
created, and the signal starts to move towards the CNS. Most often neurons conducting 
nociceptive	stimuli	are	either	Aδ	or	C-fibres.	Aδ	fibres	are	small,	myelinated,	rapidly	
conducting neurons and their activation quickly causes the sensation of sharp, easily 
localized	pain.	C-fibres	are	small,	unmyelinated	neurons	with	much	broader	sensory	
areas	 than	 the	Aδ	fibres.	C-fibre	 activation	 leads	 to	 the	 slower	 sensation	 of	 dull,	
burning pain (Basbaum et al. 2009). 
The	cell	bodies	of	the	nociceptive	neurons	(or	primary	afferents	neurons	of	the	pain	
pathway) are located in the dorsal root ganglia. From there they project to the dorsal 
horn	of	the	spinal	cord	where	the	primary	afferent	neurons	synapse	with	the	secondary	
afferent	neurons	of	the	pain	pathway.	The	nociceptive	impulse	ascends	through	the	




anterior cingulate cortex, somatosensory cortex and prefrontal cortex (Steeds, 2009) 
(Figure 1).
Figure 1.	 Ascending	 spinoreticular	 tract	 and	 descending	 pain	 pathways.	 Afferent	 pain	
pathway	ascends	towards	the	thalamus	and	cortex.	Primary	afferent	neuron	marked	in	red.	
Secondary	and	tertiary	afferents	marked	in	brown.	Descending	pain	pathway	is	activated	by	
the pain sensation. Neurons in descending pain pathway synapse with the ascending pain 
pathway on many levels modifying the pain experience. 
The pain signal is highly modulated before the actual pain sensation occurs. Pain 
modulation is conveyed back to the dorsal horn of the spinal cord via descending pain 
pathways, which can be either inhibitory or excitatory. When an individual experiences 
pain, periaqueductal grey (PAG) starts to receive input from the higher brain areas. This 
activates PAG that in turn, further activates the cells located on the rostroventromedial 
medulla	(RVM).	Different	parts	of	RVM	are	activated	in	descending	pain	facilitation	
and inhibition. Studies have recognized both OFF-cells that activate the descending 
inhibitory pain pathway and ON-cells, which activate the facilitatory pathways. The 
presence of both cell types provides a cellular explanation for the pain modulation by 
higher cortical areas. Opioids inhibit ON-cells and excite OFF-cells (Ossipov et al., 
2014). The pain signal can be inhibited in the nuclei of RVM, but the descending pain 
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pathway	also	projects	downwards	 through	 the	nucleus	 raphe	magnus	and	finally	 to	
the dorsal horn of the spinal cord. Neurons in the inhibitory descending pain pathway 
release serotonin, norepinephrine and other neurotransmitters that inhibit the activation 
of the cells in the ascending pain pathway (Figure 1). 
Acute pain is an important protective signal that prevents the individual from 
harming their body in a possibly lethal way. When a painful sensation continues 
for an extended time-period, it loses its protective nature and becomes a burden for 
the	individual.	Pain	is	usually	defined	as	chronic	if	it	has	lasted	for	more	than	three	
months or longer than the expected recovery from a tissue injury would normally 
take. In chronic pain, the pain the function of the pain sensing system is altered. The 
pathology behind a chronic pain condition can be either in the peripheral nerves, 
CNS or even in multiple locations at the same time. In peripheral nerve damage, the 
injured nerve can be sensitized to many normally non-painful stimuli. In the CNS, 
chronic pain can be a sum of many changes. Chronic pain patients usually express 
higher sensitivity to pain. Recently, increased interest has focused on the function 
of the descending pain system in chronic pain patients. MRI and fMRI imaging 
has	 shown	 anatomical	 and	 functional	 differences,	 such	 as	 abnormal	white	matter	
connectivity and regional grey matter atrophy, between chronic pain patients and 
healthy controls (Geha et al., 2008; Baliki et al., 2008). 
2.1.2 Measuring pain
Pain is always an individual experience composed of sensory-discriminative, 
affective,	 cognitive	 and	 behavioural	 components.	Nonetheless,	 in	 order	 to	 treat	
and study pain, several methods for pain assessment have been developed. Many 
of these tools are relatively simple and focus on the intensity/unpleasantness of 
pain. One such a tool is the Visual Analog Scale (VAS) that comprises a 100 mm 
line segment. With VAS the patient is asked to indicate his/her pain intensity on 
the line, 0 mm indicating no pain and 100 mm indicating the worst pain possible. 
Additionally, VAS can also have graphic designs to help patients better interpret 
the	 line	 like	 colours,	 numbers,	 faces	 indicating	 different	 pain	 intensities	 and	 a	
rising shape. VAS is widely used because of the simplicity and convenience of 
the test. Moreover, the test is reliable – although it is not suitable for cognitively 
impaired people (Hawker et al., 2011) – and it has been validated using fMRI 
imaging (Coghill et al., 2003).
Another broadly used pain-measuring tool is the Numerical Rating Scale (NRS). 
This test does not have a visual aspect like VAS, but the patient is rather asked to 
evaluate the pain intensity with a number. Generally, the range from zero to 10 is 
used with zero indicating no pain and 10 the worst pain imaginable. NRS scores of 
1-3 are considered mild, 4-7 moderate and 8-10 severe pain. Overall, the reliability 
of the test is similar to that of VAS (Hawker et al., 2011).
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There is a multitude of questionnaires for assessing chronic pain. The most common 
ones	include	the	McGill	Pain	Score	-	that	focuses	on	intensity,	affective,	sensory	and	
evaluative aspects of pain and the Brief Pain Inventory - which puts emphases on 
the location of pain and how it interferes with various aspects of life (Cleeland et 
al. 1991; Melzack, 1975; Daut, 1983). While the completion of VAS and NRS only 
takes seconds, these questionnaires require more time, but in return provide a much 
broader assessment of pain type (Hawker et al., 2011).
2.1.3 Thermal pain sensitivity
Cold sensation is mainly mediated by the TRPM8 belonging to the Transient Receptor 
Potential family, also known as cold- and menthol-sensitive receptor 1 (Bautista 
et al., 2007). This receptor is activated at skin temperatures below 26 °C, whereas 
below 10 °C it becomes inactive as the skin temperature falls to the point where cold 
starts to act as a numbing agent (Peier et al., 2002). In addition to temperatures below 
26 °C, a number of chemical agents including menthol can activate this receptor. 
TRPM8 receptors are Ca2+ permeable, non-selective cations channels expressed on 
the	surface	of	C-fibres.	There	is	also	evidence	that	cold	sensation	can	occur	through	
other mechanisms besides the activation of TRPM8. For example, TRPM8 -/- mice 
detected cold stimuli but at lower temperatures than wild-type mice. Moreover, 
TRPM8 -/- mice also tolerated noxious cold stimuli for a longer time than their 
wild-type counterparts (Bautista et al., 2007). Additionally, TRPA1 receptor can be 
a receptor for noxious cold stimuli, but so far, studies have been inconclusive of its 
role (Kim et al., 2006; Knowlton et al., 2010; Schutz et al., 2014).
Heat pain perception is also caused by the activation of a multitude of receptors 
belonging to the Transient Receptor Potential family. The most studied of these is 
the TRPV1 receptor, which senses capsaicin induced heat sensation. Other known 
heat pain receptors include TRPV2, TRPV3 and TRPV4 (Venkatachalam et al, 2007) 
which	all	activate	at	different	temperatures	to	provide	an	individual	with	a	sense	of	heat	
intensity. TRPV1 is known to activate at a temperature of 43 °C while, for example, 
TRPV2 is only activated at temperatures above 52 °C (Caterina et al., 1999) (Table 1).
Table 1. Receptors involved in thermosensation.
TRPV1 uncomfortably warm >43 °C Caterina et al., 1999
TRPV2 noxious heat >52 °C Caterina et al., 1999
TRPV3 innocuous heat 30-39 °C Peier et al. 2002
TRPV4 innocuous heat 25-34 °C Watanabe et al., 2002




The cell bodies of these thermosensory cells locate in the trigeminal ganglia and 
dorsal root ganglia. Centrally they project to the lamina I and outer layer of lamina 
II of the dorsal horn of the spinal cord. Temperature signals reach the brain via the 
lateral spinothalamic tract, while noxious signals are additionally carried via the 
spinoreticular tract (Almeida et al., 2004; Willis et al., 1997; Giordano 2005). In healthy 
humans, stimulation of the forearm skin with innocuous cold leads to activation of the 
contra- and ipsilateral-posterior insular cortices and the primary somatosensory area. 
In contrast, noxious cold stimuli activate the contra- and ipsilateral-insular cortices, 
secondary somatosensory cortices and the cingulate cortex (Maihöfner et al., 2002).
Cold pain thresholds vary much more between individuals than hot pain thresholds. 
Furthermore, patients also describe the cold pain sensation with a wide range of 
qualitative	words,	whereas	heat	pain	is	 typically	defined	as	burning	(Morin	et	al.,	
1998). Interestingly, the cold pain threshold has also been shown to remain relatively 
steady when the same individual is retested (Moss et al., 2016).
Experimental pain sensitivity has been hypothesised to predict the postoperative 
pain outcomes and act as a tool for clinicians to predict which patients require 
more analgesics after surgery. So far, studies have been inconclusive on whether 
experimental	 pain	 measurements	 have	 any	 clinical	 significance.	A	 recent	 review	
showed that in spite of extensive research, no consistent association between 
experimental pain variables and pain after surgery exists (Sangesland et al., 2017).
Although other nociceptive stimuli - like chemical and mechanic - are known to exist 
in addition to thermal stimuli, these are not addressed within this thesis.
2.1.4 Postoperative pain
The intensity of postoperative pain depends on many aspects including patient and 
surgery-dependent factors. The characteristics of the operation predispose patients to 
different	types	and	intensities	of	pain	depending	on	the	invasiveness	of	the	surgery,	
the tissue being operated on and the site of the operation. Post-operative pain can 
comprise of only one type of pain, but it can also consist of a mixture of nociceptive, 
neuropathic and visceral pain.
Traditionally, greater pain intensities are expected after surgeries that are highly 
invasive,	especially	in	areas	highly	innervated	with	sensory	nerve	fibres.	However,	a	
study by Gerbershagen et al. showed that many minor, everyday procedures resulted 
in surprisingly high postoperative pain intensities. Such types of surgeries included 
appendectomy, haemorrhoidectomy and tonsillectomy, which ranked among the 25 
operations with the highest post-operative pain intensities. Of the 25 operations with 
highest	postoperative	pain	intensities,	17	were	trauma/orthopaedic	and	five	abdominal	




operative morphine equivalents administered after these operations were much lower 
than for the more extensive surgeries, even though the patients reported high post-
operative pain intensities (Gerbershagen et al., 2013).
With the exception of the type of surgery, not many surgery-related related predictive 
factors	of	post-operative	pain	intensities	have	been	identified.	Intraoperative	opioid	
use or preoperative patient education about surgery showed no association to post-
operative pain intensity. Additionally, results on the correlation between incision 
size, duration of the surgery, number of previous surgeries and post-operative pain 
have been inconclusive (Ip et al., 2009).
Many	 patient-related	 factors	 affecting	 postoperative	 pain	 intensities	 are	 known.	
In our cohort factors associated with postoperative pain intensities in prior studies 
include type of surgery (breast conserving/mastectomy with sentinel node biopsy/
axillary clearance), age and experimental heat pain intensity (Kaunisto et al., 2013).
One	of	the	most	widely	studied	factors	affecting	postoperative	pain	is	anxiety,	which	
has been shown to increase perceived pain intensities and post-operative analgesic 
requirements (Hui et al., 2009). Interestingly, preoperative diazepam has been found 
not	to	affect	post-operative	pain	outcomes	or	analgesic	requirements	(Caumo	et	al.,	
2002).	Other	 psychological	 factors	 shown	 to	 affect	 postoperative	 pain	 intensities	
are	 the	 expectance	 of	 pain,	 depressed	mood/negative	 affect,	 pain	 self-distraction	
and catastrophizing as a coping mechanism and personality traits (for example 
neuroticism, hostility) (Sipilä et al., 2017; Ip et al., 2009).
Age has also been shown to decrease both post-operative pain intensities and 
analgesic consumption. With advancing age, the nervous system is exposed to many 
degenerative processes such as atrophy in the cortex, changes in neurotransmitter 
levels	and	the	density	of	peripheral	nerve	fibres	(Fjell	et	al.,	2009;	Ko	et	al.,	1997.	
Verdú et al., 2000). All these processes change how pain is perceived. The changes 
in analgesic requirement have been hypothesised to be due to a lower percentage 
of body water as well as decreased liver and kidney function, which alters both the 
metabolism and excretion of analgesics (Liukas et al., 2011; Saari et al., 2012).
The	effect	of	gender	on	postoperative	pain	is	still	under	dispute.	Some	studies	have	




pain	 inhibition	 in	women	as	well	as	differences	 in	central	sensitization,	hormonal	
differences	and	social	aspects	toward	pain	behaviour	(Pereira	et	al.,	2015).	
The	 effect	 of	 BMI	 on	 post-operative	 pain	 intensity	 is	 also	 unclear.	 Only	 a	 few	
studies	have	addressed	the	effect	of	BMI	to	post-operative	pain.	One	study	found	
association with increased postoperative pain intensities and high BMI, whilst 
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another determined no association (Ip et al., 2009). In our cohort, BMI appeared not 
to	affect	post-operative	pain	intensity	(Kaunisto	et	al.,	2013).
Tobacco smoking has been shown to associate with higher postoperative pain 
intensities and an increase in opioid consumption (Bortoluzzi et al., 2012; Chiang et 
al., 2016; Yang et al., 2012). Although the mechanism that results in these pain intensity 
differences	 remains	 unknown,	 it	 could	 be	 partially	 due	 to	 chronic	 inflammation	
processes,	deficient	wound	healing	and	a	higher	occurrence	of	complications	(Myles	
et al., 2002; Sorensen et al., 2005; Lewin et al., 2014). The reason for the association 
between tobacco smoking and opioid requirements is unclear, but it is thought to 
be due to pharmacokinetic or demographic factors (Shi et al., 2010). In our study 
sample, previous smoking was associated with decreased experimental heat pain 
sensitivity	 but	 otherwise	 smoking	 did	 not	 affect	 pain	 intensities	 or	 oxycodone	
consumption (Kaunisto et al., 2013).
2.1.5 Management of post-operative pain
Modern	day	surgery	requires	efficient	analgesia	and	good	pain	management	helps	the	
body to cope with the stress caused by surgery and enhances recovery. Opioids are 
the gold standard analgesic for moderate to severe acute postoperative pain. Often 
the pain management protocol starts before anaesthesia with premedication (usually 
NSAID or paracetamol). Induction of anaesthesia begins with an intravenous (i.v.) 
dose of a rapidly acting opioid such as remifentanil or fentanyl. During surgery, 
more opioid is administered if the patient shows signs of pain, such as an increased 
heart rate. Before reversing anaesthesia, the wound itself is often anaesthetised with 
a local anaesthetic to reduce nociceptive pain. 
In the post-operative care unit (PACU) patients are usually given i.v. opioids with 
dosing adjusted in relation to the patient’s age, weight and pain intensity. The goal 
is that the pain intensity is no more than mild (NRS 0-3). In the PACU, patients 
are monitored intensively and once they have recovered from the anaesthesia and 
symptoms (e.g. pain and nausea) are under control they can be moved to the ward 
or in case of minor surgeries, discharged. In the ward, patients receive analgesics 
either with a PCA or by oral administration. Usually NSAID or paracetamol is used 
as a base analgesic and opioid is only administered if needed. Patients must still be 
monitored and pain intensity evaluated regularly to ensure adequate pain relief.
2.2 Opioids
Opioids are a group of drugs that interact with G-protein coupled opioid receptors 
(mu, kappa, and delta). Endogenous opioid system is a vital part of the central and 
peripheral neurotransmitter networks. Endogenous opioids include i.e. endorphins, 




pain e.g. after surgery or trauma, and cancer pain. Currently the opinion is opioids 
produce analgesia mainly by activating the mu-opioid receptors in the CNS.
Opioid receptors are highly expressed in subcortical regions of the CNS such as 
brainstem, midbrain periaqueductal grey, ventral tegmental area, nucleus raphe 
magnus, the rostral ventral medulla, hypothalamus, amygdala, thalamus and cortex, 
from which descending pain pathways originate. Opioids are thought to activate 
the descending pain pathways through the disinhibition of GABAergic interneurons, 
which leads to activation of descending neurons that inhibit signal transmission in 
the spinal cord. 
 In the spinal cord opioid receptors can be found on the surface of pre- and 
postsynaptic cell membranes as well as interneurons. Opioids produce analgesia by 
inhibiting spinal nociceptive transmission. The activation of opioid receptors on the 
presynaptic neuron reduces cAMP signalling and decreases the activity of voltage-
gated calcium channels. This inhibits the release of neurotransmitters to the synaptic 
cleft thus preventing the pain signal transmission. The activation of opioid receptors 
located on the postsynaptic cell membrane causes hyperpolarization by activating 
the	potassium	influx	channels	(Trang	et	al.,	2015).	
2.2.1 Oxycodone
Synthesized in 1917 in Germany, this semi-synthetic opioid has replaced morphine 
as an analgesic due to higher oral bioavailability, more rapid penetration through 
the	 blood-brain-barrier,	 longer	 duration	 of	 action	 and	 less	 side	 effects	 (Olkkola	
el al., 2013). Oxycodone is derived from codeine and the chemical structures of 
oxycodone and codeine are quite similar with exception that oxycodone has one 
extra carbonyl and hydroxyl groups and lacks a double bond (Figure 2). Oxycodone 
is used increasingly worldwide for moderate and severe acute pain as well as chronic 
pain conditions. In Finland, oxycodone has been the most used post-operative opioid 
analgesic since the 1970s. 




When	 administered	 intravenously,	 the	 analgesic	 effect	 of	 oxycodone	 commences	
after 5-8 minutes (Leow et al., 1995), whereas after oral administration, the analgesic 
effects	are	noticed	after	10-30min.	Oxycodone	has	a	relatively	high	oral	bioavailability	
of 60-80%, which greatly exceeds that of morphine (15-40%) and additionally the 
interindividual variation in bioavailability is smaller with oxycodone than morphine, 
making it easier to administer. The peak plasma concentration of oxycodone is 
reached after 1.5-2 hours when administered as oral solution. Oxycodone is more 
hydrophopic than morphine. About 40% of oxycodone is bound to plasma proteins 
when studied in vitro and the elimination half-life for oxycodone is 3-5h (Olkkola 
et al., 2013).
Oxycodone is metabolized primarily by CYP3A4/5 and CYP2D6 enzymes located in 
enterocytes of the small intestine and hepatocytes with the main metabolic pathway 
involving N-demethylation to noroxycodone via CYP3A4. Noroxycodone has a weak 
opioid potency and is thought have no major role in oxycodone-induced analgesia. 
However, O-demethylation by CYP2D6 yields oxymorphone - a strong mu-opioid 
receptor agonist - that has been suggested to play a role in oxycodone analgesia. 
The	 affinity	 of	 oxymorphone	 to	 the	mu-opioid	 receptor	 could	 be	 up	 to	 40-times	
higher than that of oxycodone (Lalovic et al., 2006). So far, the data regarding the 
clinical	significance	of	oxymorphone	has	been	inconclusive	since	the	concentration	
of the metabolite remains low in plasma and possibly in the CNS as well (Heiskanen 
et al. 1998). Both noroxycodone and oxymorphone are further metabolised to 
noroxymorphone by CYP3A4/5 and CYP2D6, respectively. Noroxymorphone has 
about	two	to	three	times	higher	affinity	to	the	mu-opioid	receptor	than	oxycodone,	
nonetheless,	it	penetrates	the	BBB	poorly	and	therefore	has	mainly	peripheral	effects	
(Lalovic et al., 2006). A minor metabolic pathway of ketone reduction yields two 
stereoisomers of oxycodol from oxycodone, noroxycodol from noroxycodone, and 
oxymorphol from oxymorphone (Figure 3.).
There is evidence that oxycodone accumulates in the CNS. Though no human 
data exist, studies in rats has shown the brain-plasma ratio to be 2:1 (Lalovic et 
al., 2006). This was hypothesized to be due to active transport through the BBB 
(Bostrom et al., 2008), as oxycodone has been shown to cross the BBB up to 
7 times faster than morphine (Villesen et al., 2006). So far, the most promising 
candidate for this protein has been the pyrilamine transporter that has been shown 
to partly mediate transportation of oxycodone to the CNS in rats. No human data 
for	this	or	any	other	transporter	is	available.	The	effect	of	P-glycoprotein	on	the	
CSF concentrations of oxycodone has been debated. Initially, P-glycoprotein 
was thought to have no role in the pharmacokinetics of oxycodone, though later 
it was demonstrated that oxycodone, like morphine, acts as a substrate for the 
P-glycoprotein	and	therefore	is	possibly	subjected	to	active	efflux	transportation	
(Hassan et al. 2007).
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Oxycodone and its metabolites are all excreted through the kidneys either in a 
conjugated	 or	 unconjugated	 form.	 Both	 renal	 and	 hepatic	 impairment	 influence	
the	maximum	plasma	concentrations	and	the	effect	time	of	oxycodone.	In	a	study	
published in 2015, severe renal impairment almost doubled the maximum plasma 
concentration after a 10mg oral dose (Malhotra et al., 2015). The AUC from detection 
to last detectable concentration rose 1.5 times with moderate renal function and more 
than doubled with severely impaired kidney function when compared to normal 
kidney function. Similarly, moderate hepatic impairment doubled the maximum 
plasma concentration and the AUC after a single dose of 10mg oxycodone when 
compared to normal hepatic function (Malhotra et al., 2015).




Oxycodone is a relatively selective mu-opioid agonist, but it does bind to kappa- 
and	 delta-receptors	 to	 some	 extent.	 The	 binding	 affinity	 of	 oxycodone	 to	 mu-
opioid receptor is 5-40 times lower when compared with morphine (Lalovic et al., 
2006; Lemberg et al., 2006). In addition, oxycodone also activates 4-8 times less 
intracellular G proteins than morphine (Lalovic et al., 2006). There is evidence that 
oxycodone	G	protein	 activating	potency	varies	 in	 different	 parts	 of	 the	CNS	and	
that	this	potency	can	even	be	altered	by	different	disease	states	such	as	bone	cancer	
(Nakamura et al., 2013). 
Besides analgesia, oxycodone also causes decreased alertness, nausea, changes in 
mood, pruritus and pupil constriction (Lalovic et al., 2006). Oxycodone, like other 
opioids,	 also	 has	 antitussive	 effects	 and	 can	 cause	 respiratory	 depression	 (Chang	
et	 al.,	 2010).	 Furthermore,	 other	 known	 side	 effects	 include	 constipation,	 urinary	
retention and sweating (Kalso et al., 1990). 
2.2.2 Studying the analgesic effect of opioids: dose vs. plasma 
concentration
When	studying	the	analgesic	effects	of	opioids	in	humans,	the	most	utilized	measure	
is	 the	 dose:	Either	 the	 analgesic	 effect	 of	 a	 fixed	 dose	 is	 determined	 or	 the	 dose	
required to achieve a pre-set analgesia status is measured. Opioid dose can be 
monitored easily, which makes it a tempting variable for research. Nevertheless, 
as	 the	final	effect	of	opioids	 is	conveyed	by	 the	mu-opioid	 receptors	 in	 the	CNS,	
many pharmacokinetic events can alter the amount of opioid reaching the mu-opioid 
receptor before any analgesia can occur. Therefore, there is always a degree of 
inaccuracy when determining analgesia from the dose required. 
In order to achieve the best accuracy to estimate how much opioid is needed to 
activate the opioid receptors, measurement of CSF concentrations would be the 
favoured	clinical	method.	Two	 studies	have	addressed	 the	difference	 in	 analgesic	
doses between epidurally and intravenously administered oxycodone (Backlund et 
al., 1997; Kokki et al., 2014). In the study by Kokki et al. the amount of oxycodone 
administered was standardized and no analgesic CSF concentration could be 
determined, whereas in the research of Bäcklund et al. oxycodone concentrations 
were only measured from the plasma. Measurement of the CSF concentration of any 
opioid requires insertion of a spinal catheter and frequent sample collection must be 
performed. Furthermore, the procedure is invasive and includes a risk for headache 




Genetics is the study of the science of heredity, dealing with resemblances and 
differences	of	related	organisms	resulting	from	the	interaction	of	their	genes	and	the	
environment. 
The human genome consists of double-stranded deoxyribonucleic acid (DNA) 
which forms the genetic code of an individual. The human genome is estimated to 
have around 20,000-25,000 genes (International Human Sequencing Consortium, 
2004). These comprise only a fraction of the complete human genome even when 
all the areas regulatory regions are included. In addition, the genome contains 
many areas that code for non-protein molecules like micro-RNAs. Most of the 
genome consist of DNA-areas with unknown function (The ENCODE Project 
Consortium, 2012). 
Each gene has regulatory areas normally located upstream from the coding region 
and these usually contain a number of enhancer/silencer sequences and promoter 
sequences. The enhancer/silencer sequences can alter the transcription activity of 
the gene. The gene itself consist of exon and intron sequences: Intron sequences 
are transcribed to the premature messenger RNA (mRNA) but are then removed 
by	splicing	before	translation.	In	contrast,	the	exons	are	first	transcribed	to	mRNA,	
before later being translated to proteins. 
The individuality of each person’s genetic makeup comes from DNA polymorphism, 
which	is	defined	as	the	occurrence	of	two	or	more	alleles	at	one	locus	in	the	same	
population, each with appreciable frequency (Cavalli-Sforza et al., 1971). Some 
common types of genetic polymorphism are listed in Table 2.
Table 2. Common types of genetic polymorphisms. Bp = base pair, kb = kilo base pair 
(1,000	base	pairs),	Mb	=	mega	base	pair	(1,000,000	base	pairs).	Modified	from	Genomic	and	
personalized medicine, Chapter 1 (Willard 2013)
Type of polymorphism Change Possible effect
Single nucleotide 
polymorphism
Alters one nucleotide ·Transcription +/- 
·Protein	configuration	alteration	
·Often	no	effect
Insertion / deletion Inserts or deletes a 
sequence of DNA sized 1 




Copy number variants Repeats a sequence sized 1 
kb - 1Mb in the DNA strand
·Transcription +/-
Inversion A part of DNA breaks 
loose, rotates 180° and 







In genetic studies, the individual’s genetic code or genotype of certain polymorphic loci 
must	be	determined.	This	can	be	done	in	various	extents.	When	a	specific	candidate	
polymorphism or gene is hypothesized to have an association with the studied 
phenotype, only this part of genome needs to be analysed by sequencing or genotyping 
methods. If the genome phenotype interaction needs to be examined on a larger scale, 
genome-wide SNP genotyping, exome or genome sequencing can be used. In the case 
of genome sequencing, the nucleotide order of the whole genome is determined, while 
in exome sequencing only the protein coding parts of the DNA are sequenced. Exons 
only	comprise	about	1%	of	the	genome	so	exome	sequencing	produces	significantly	
less data than genome sequencing. When looking at polymorphism associations with 
a studied phenotype on a genome wide scale, the alleles of hundreds of thousands to 
millions of previously known polymorphisms are determined from the study population, 
after which a genome wide association study (GWAS) is performed. GWAS has made 
it possible to explore genomic-phenotype associations on a large scale. The method is 
best	used	for	diseases	with	multiple	effecting	genes,	since	GWAS	has	poor	recognition	
of rare variants or polymorphisms with low allele frequencies. GWAS requires a large 
sample	size	since	the	effect	of	 individual	genetic	variants	on	the	studied	phenotype	
is usually very small. In addition, any associations found must also be replicated in 
another cohort and preferably studied with targeted gene sequencing before clinical 
significance	can	be	determined	(Bush	et	al.,	2012).
In practise, associations between a genotype and certain phenotype are determined by 
comparing allele or genotype frequencies between cases of interest and appropriate 
controls. If the allelic frequency is much higher in case-group, there is a positive 
association to the studied phenotype. For continuous phenotypes (e.g. height), the mean 
values of each genotype are compared and if the means of the studied phenotype vary 
significantly	between	the	different	genotypes,	an	association	is	present.	Nevertheless,	
the	final	interpretation	of	the	data	can	be	difficult,	especially	as	the	case	and	control	
populations should be matched for ancestry. Furthermore, an association does not 
equal causation as an association between a polymorphism and phenotype is only a 
starting	point	when	studying	the	effect	of	genetics	on	a	clinical	phenotype.	
When a rare, high-impact variant is expected to cause the studied phenotype, 
sequencing	methods	are	used.	Previously,	targeted	Sanger	sequencing	of	a	specific	
gene was frequently used due to high-cost of sequencing and such targeted 
sequencing	 can	be	quite	 effective	 in	 recognising	 rare	variants	 as	 it	 allows	 a	high	
depth of coverage. Nonetheless, in order to utilize this method, a candidate mutation 
or	 gene	 first	must	 be	 assumed	 to	 exist.	Moreover,	 targeted	 sequencing	 also	 only	
produces data from the chosen area so many important variations can be missed. As 
the	cost	of	sequencing	has	significantly	decreased	in	recent	years,	it	is	now	possible	
to use exome and genome sequencing. Exome and genome sequencing look at the 
genetic code on a wider scale making it possible to observe more gene-phenotype 




which is often quite hard to interpret since every individual’s genome contains tens 
of	thousands	of	rare	variations	with	unknown	significance	(Tennesen	et	al.,	2012;	
Nelson et al., 2012). Consequently, the analysis of the sequenced data generally 
targets	a	few	specific	areas	of	interest.	
2.3.1 Genetics of pain and analgesia
2.3.1.1 Genetics of pain
The individuality of pain sensitivity and analgesic requirements have raised the 
question	as	to	the	role	of	genetics	in	pain	susceptibility	and	effectiveness	of	analgesics.	
Multiple studies have examined potential gene polymorphism in order to identify the 
aetiology behind this interindividual variability. Several genetic variants have been 
shown to be associated with pain intensity, threshold and opioid requirements, but 
so	far,	their	effect	has	been	small	when	compared	with	known	phenotype-phenotype	
interactions like pain intensity and anxiety. 
Heritability of pain varies greatly and there are a number of rare pain syndromes that 
are caused by mutation in a single gene. Usually these single-gene disorders result 
in dramatic phenotypes, like in the case of HSAN2 syndrome caused by missense 
mutations in the protein kinase PRKWNK1 that results in an individual’s total 
loss of all sensation. In addition, mutations in the sodium channel NaV1.7 coding 
SCN9A have also been determined to cause multiple genetic pain disorders (Dreth 
et al., 2007). In addition to rare pain syndromes, a common genetic background has 
been	 shown	 to	 affect	 pain	 sensitivity	with	most	 experimental	 pain	 types.	 Studies	
conducted with monozygotic and dizygotic twins have shown the genetic component 
of	different	experimental	pain	intensities	and	thresholds	can	explain	22%	to	60%	of	
the variance observed (Norbury et al., 2007; Nielsen et al., 2008).
Genes	 can	 potentially	 affect	 pain	 intensity	 at	 any	 point	 of	 the	 pain	 pathway.	An	
example	for	peripheral	effect	is	the	TRPA1 gene coding for TRPA1 receptor. TRPA1 
rs1198795	has	been	shown	to	alter	reported	cold	pain	intensity	significantly	(Kim	
2006). Pain processing occurs also higher up in the pain pathway with examples 
of	genes	expressed	 in	 the	CNS	that	are	hypothesized	 to	affect	pain	 intensities	are 
OPRM1, FAAH and COMT. 
Genetics	of	different	pain	phenotypes	have	been	extensively	 studied,	but	 thus	 far	
only one small-scale exome sequencing study focusing on experimental heat pain 
has	 been	 performed,	 which	 resulted	 in	 no	 clear	 findings.	 The	 most	 significant	
associated gene was GZMM which codes for serine protease protein expressed 
in natural killer cells and lymphocytes. A later network analysis also showed an 





Other studies, which take the candidate gene approach, have found association 
between experimental pain and COMT, OPRM1, FAAH, GCH1, MC1R and TRPA1 
variants (Kim et al., 2009a).
Acute post-operative pain has been addressed in one GWAS. In this study, the main 
studied phenotype was analgesia onset after NSAID administration and results 
showed	that	there	were	no	significant	associations	to	post-operative	pain	intensity.	
(Kim et al., 2009b). In addition to the GWAS, there have also been studies that 
investigated potential genes associated with post-operative pain (Kim et al., 2009a).
2.3.1.2 Pharmacogenetics of analgetics
Pharmacogenetics	is	the	scientific	speciality	studying	the	drug	response	variability	
due	 to	 genetic	 factors.	 Genetic	 polymorphism	 can	 affect	 the	 drug	 response	 on	
many	 levels,	 for	example,	genetic	variants	can	affect	how	 the	drug	 is	absorbed,	
metabolized, bound to proteins and secreted from the body or change the 
pharmacodynamics	 of	 the	 drug.	 Significant	 drug-genotype	 interactions	 have	
already	been	revealed,	such	as	the	effect	of	CYP2D6 polymorphisms on codeine 
metabolism to morphine (Dayer et al., 1988). This has been demonstrated by a 
reported incident where paediatric patient experienced morphine overdose after 
codeine administration due to a version of the CYP2D6 enzyme converting codeine 
to morphine much more rapidly than expected (Orliaguet, 2015). Currently a gene 
test to determine CYP2D6 genotype is used clinically to evaluate the dose and 
duration of action of a multitude of drugs. 
Post-operative	 opioid	 requirement	 varies	 significantly	 between	 individuals.	Many	
potential genetic contributors to this variance have been studied, but to date the 
results	have	been	either	conflicting	or	the	associations	weak.	In	a	recent	GWAS	Cook-
Sather	et	al.	found	multiple	nominally	significant	associations	between	SNPs	in	the	
TAOK3, TEC and MFI2 gene regions and post-operative morphine requirements in a 
paediatric surgery population (Cook-Sather et al., 2014).
2.3.2 Genes possibly affecting postoperative pain and analgesia
2.3.2.1 OPRM1
OPRM1, located on the long arm of chromosome 6, is the gene coding for the mu-
opioid receptor. The gene spans around 230,000 base pairs and contains 17 exons. 
OPRM1 is undergoes extensive alternative splicing and several of alternatively 
spliced	variants	have	been	identified.	OPRM1 is primarily expressed in the CNS, but 
also in the adrenal gland, thyroid gland and testis (NCBI Gene Database: OPRM1).
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Of the more than three thousand known polymorphisms in the OPRM1, rs1799971, 
(g.[118A>G]) is of special interest. This polymorphism changes aspargine 40 to 
aspartate	40	(p.[Asn40Asp]),	therefore	altering	the	configuration	of	the	final	receptor	
protein. This change in the amino acid sequence of the extracellular N-terminal end 
leads to a loss of a glycosylation site, which has been determined to destabilize the 
receptor. The half-life of the Asp40 (mutated) receptor was only 11.6 h compared to 27.7 
h for Asn40 (wild-type) receptor (Huang et al., 2012). Rs1799971 polymorphism has also 
been	shown	to	alter	the	receptor’s	binding	potential	to	β-endorphin	and	possibly	to	other	
opioids, as well as mRNA expression (Bond et al., 1998; Zhang et al., 2005), which 
could change the downstream signalling caused by opioids binding to the receptor. 
OPRM1 rs1799971 has been extensively associated with many phenotypes (Table 
4).	The	effects	of	rs1799971	on	opioid	requirements	and	pain	intensity	have	been	
researched extensively, particularly with morphine or fentanyl. Prior to this study, 
only two studies have looked at the association between oxycodone requirement and 
rs1799971. (Bruehl et al., 2006; Zwisler et al., 2012) (Table 3.). 
Many of the studies that examine OPRM1	 rs1799971	 polymorphism’s	 effect	 on	
post-operative pain and opioid requirements have been performed with relatively 
small patient groups (50-200 patients) and showed variable results. The three largest 
studies conducted with more than 500 patients showed that G-allele carriers required 
more opioids post-operatively and also reported higher post-operative pain scores 
(Tan et al., 2009; Sia et al.,2013; Sia et al., 2008) (Table 3.). A recent review article 
and	 meta-analysis	 concluded	 that	 rs1799971	 does	 affect	 the	 post-operative	 pain	
intensities	and	opioid	requirements	during	the	first	24h	but	that	this	effect	wears	off	
before 48h has passed (Ren et al., 2015). The analysis was performed by comparing 
major allele homozygote (AA) individuals with G-allele carriers, so the possible 
differences	between	heterozygous	and	minor	allele	homozygous	(GG)	 individuals	
could not be estimated. There is evidence that GG individuals would require more 
opioids when compared to patients who were heterozygous for the polymorphism 
(Zhang et al., 2010; Zhang et al., 2011; Fukuda et al., 2010).
The allele frequency of the OPRM1	 polymorphism	 varies	 greatly	 in	 different	
populations. G-allele frequency is highest among Japanese (48%) and most rare 
among African populations from Nigeria, Gambia and Sierra Leone (0%). In Finland, 
the frequency of G-allele is about 20%, which is similar to other Northern European 
populations (NCBI Variation Viewer, Sequencing Initiative Suomi Project (SISu)). 
When	the	gene’s	effect	in	different	ethnic	groups	was	studied,	it	emerged	that	the	gene	
may	alter	experimental	pain	 intensity	differently	 in	people	with	different	ancestry	
(Hastie et al., 2012). Nevertheless, there are currently no studies that investigate the 
combined	effect	of	ethnicity	and	OPRM1 rs1799971 on postoperative pain intensity 
or opioid requirement. However, in many studies both ethnicity and rs1799971 
polymorphism	have	been	 shown	 to	be	 significant	 independent	 factors	 (Tan	et	 al.,	













Table 3. Studies assessing OPRM1 rs1799971 and postoperative pain intensity and opioid consumption. A = Asian, I = Indian, C = Caucasian, M = multiple.
OPRM1 rs1799971 
Genotype
Effect of  










Tan et al 2009 994 A, I Caesarean section morphine 0.39 389 435 170 increase increase
Sia et al 2013 973 A, I Hysterectomy morphine 0.39 354 474 145 increase increase
Sia et al 2008 585 A Caesarean section morphine 0.34 271 243 80 increase increase
Fukuda et al 2009 280 A Orofacial surgery fentanyl 0.44 86 143 51 no	effect no	effect
Zwisler et al 2012 266 C Thyroidectomy and others oxycodone 0.10 219 43 4 no	effect no	effect
De Gregori et al 2016 201 C Major abdominal surgery morphine 0.18 136 56 9 no	effect increase
Kim et al 2013 196 A Hysterectomy fentanyl 0.39 72 96 28 n/a no	effect
Zhang et al 2010 174 A Hysterectomy or myomectomy fentanyl 0.31 86 67 21 no	effect increase
Zhang et al 2011 165 A Hysterectomy or myomectomy fentanyl 0.32 80 63 22 no	effect increase
Hayashida et al 2008 138 A Abdominal surgery morphine or 
fentanyl
0.45 41 70 27 n/a increase
Zhang et al 2013 128 A Gastrectomy fentanyl 0.37 54 53 21 n/a no	effect
Chou et al 2006b 120 A Total knee arthroplasty morphine 0.49 62 27 11 no	effect increase
Thomazeau et al 2016 109 M Knee replacement morphine 0.08 90 16 1 no	effect no	effect
Fukuda et al 2010 108 A Mandibular osteotomy fentanyl 0.46 31 54 23 n/a increase
Kolesnikov et al 2011 102 C Radical prostatectomy and 
hysterectomy
morphine 0.11 82 17 3 no	effect no	effect
Janicki et al 2006 101 C Laparoscopic surgery morphine 0.16 70 30 1 no	effect no	effect
Lee et al 2016 88 A Tonsillectomy morphine 0.28 66 38 14 increase no	effect
De Gregori et al 2013 98 C Major abdominal surgery morphine 0.18 67 26 5 n/a no	effect
Chou et al 2006a 80 A Hysterectomy morphine 0.34 43 19 18 no	effect increase
Cobault et al 2006 74 M Colorectal surgery morphine 0.04 57 1 2 n/a no	effect






0.14 51 15 2 increase no	effect
Bruehl et al 2006 48 M Coronary artery bypass Morphine, 
oxycodone
0.13 37 10 1 n/a no	effect
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Postoperative pain Negative Walter 2009
Experimental pain Inconclusive Fillingim 2005
Cancer pain Negative Walter 2009
Chronic pain Negative Janicki 2006
Opioids
Postoperative opioid consumption See Table 3.
Postoperative nausea and vomiting Negative Chou 2006a, Zhang 
2011, Sugino 2014
Severe outcome after drug overdose Positive Manini 2013
Opioid dependence Positive Haerian 2013, Kumar 
2012
Addiction
Substance dependence Positive Schwantes-An 2016
Food addiction No Davis 2014
Alcohol induced euphoria Positive Ray 2004, Berettini 2016
Alcohol addiction Positive / No Kumar 2012, Rouvinen-
Lagerström 2013
Tobacco smoking Inconclusive Frances 2015, Verhagen 
2012, Wang 2015
Naltrexone	effect:	relapse	rate Negative Chamorro 2012
Naltrexone	effect:	abstinence No Chamorro 2012
Somatic health
Breast cancer incidence Positive Cieslinska 2015
Breast cancer mortality Negative Bortsov 2012
Breast cancer stage at diagnosis Negative Bortsov 2012
HIV infection severity Positive Proudnikov 2012
HIV	treatment	efficacy Negative Proudnikov 2012
Epilepsy (IGE and IAE) No / Positive Barratt 2006, Sander 
2000
Pruritus in primary biliary cirrhosis Negative Wei 2008




Ding 2013, Sery 2010
Suicidal thoughts No Arias 2011
Other
Speed dating success (women / men) Positive / 
Negative
Wu 2016
Reinforcement learning Negative Lee 2011
Venlafaxine	effectivity	on	anxiety	disorders No Cooper 2013
Preference for high fat, high sugar foods Positive Davis 2011
Binge eating disorder Positive Davis 2009
Obesity Negative Davis 2009
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2.3.2.2 FAAH and the endocannabinoid system
The endocannabinoid system consists of the endocannabinoid receptors located 
in various parts of the CNS, peripheral tissues and their endogenous ligands. The 
most expressed receptors are the CB1 and CB2 receptors (Lu et al., 2016), which are 
both G protein coupled receptors that inhibit the intracellular cAMP cascade. CB1 
receptors are highly expressed in the CNS, particularly in the cortex, basal ganglia, 
hippocampus, and cerebellum. They usually locate at the axon terminal or in its 
close proximity, but not in the active zone. CB2 receptors are less abundant in the 
neurons and locate mainly on immune-modulating cells, including microglia in the 
brain. The hypothesis is that they act as immunomodulatory agents. In addition, 
CB2 receptors might also play a role in pathological processes such as nerve injury. 
Endocannabinoids also activate other receptors such as peroxisome proliferator 
activated receptors (PPARs) and TRP channels (Lu et al., 2016).
Endocannabinoids comprise of a common backbone structure that consists of 19 
carbon atoms and an individual polar head group (Freund et al., 2003) (Figure 4). 
The most studied and therefore best-known endocannabinoids are N-arachidonoyl 
ethanolamide (AEA; anandamide) and 2-arachidonoyl glycerol (2-AG). Both 
endocannabinoids are produced on demand by one or two rapid enzyme reactions 
from precursors in the cellular lipid membrane, and are then released straight to the 
extracellular space. 2-AG acts as a strong agonist for both CB1 and CB2 receptors, 
while anandamide is a weak agonist for CB1 and an extremely weak agonist for the 
CB2 receptor. Activation of CB1 or CB2 receptors exerts diverse consequences on 
cellular physiology, including synaptic function, gene transcription and cell motility 
(Lu et al., 2016).
Figure 4. The common 19-coal structure of endocannabinoids and the R-groups of 
anandamide and 2-AG. 
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After release to the synaptic cleft, anandamide is taken up by a transporter on the glial 
cells and is then hydrolysed by FAAH to arachidonic acid and ethanolamine (Figure 
5). Another metabolic pathway for anandamide goes through cyclo-oxygenase 2 
(COX-2) and yields prostamides. 2-AG is degraded primarily by monoacylglycerol 
lipase alpha/beta domain-containing hydrolase 6 and alpha/beta domain-containing 
hydrolase 12 (Figure 7). Additional minor metabolic pathways include oxidation by 
COX-2 and hydrolysis by FAAH (Lu et al., 2016).
FAAH is capable of hydrolysing many fatty acids. The inhibition of FAAH raises 
concentrations of ethanolamides, such as anandamide, palmityol and oleonyl 
amides, which act on both CB1 receptors and a multitude of other receptors outside 
the endocannabinoid system. This has made FAAH an interesting target for 
pharmacological interventions and several studies have investigated the association 
between FAAH and clinical conditions such as obesity, addiction, neurodegenerative 
diseases	and	inflammatory	diseases	(Alhouayek	et	al.,	2012;	Engeli	2008;	Micale	et	
al., 2007),




Figure 6. Encocannabinoid activity in the synapse. After the activation of the postsynaptic 
neuron AEA is released to the synaptic cleft where it activates CB1 receptor inhibiting the 
release of neurotransmitters. AEA is removed from the synaptic cleft by a unknown transporter 
and the hydrolysed by FAAH: NT=neurotransmitter, R=receptor, AEA=anandamide, 
CB1=cannabinoid receptor 1, T=transporter, FAAH=fatty acid amide hydroxylase, Et= 
ethanolamine, AA=arachidonic acid 
The gene coding for FAAH, located in the short arm of chromosome 1, comprises 
of almost 20,000 base pairs and contains 15 exons. FAAH is expressed in tissues 
throughout the body, with the highest levels of expression occurring in the prostate, 
testis, thyroid, small intestine, colon and kidney. There are currently over 1,700 
known variants in FAAH, of which, only 48 have a minor allele frequency above 5%. 
Of these, 42 are single nucleotide variants, four deletions and two insertions (NCBI 
Gebe Database: FAAH). The most interesting is a single nucleotide polymorphism 
rs324420 that causes a missense mutation changing proline to threonine in the 
surface loop on the cytoplasmic face of FAAH that reduces the expression of FAAH 
in human T-lymphocytes by 50%. So far, the change in expression seems to be as a 
result of post-translational modulations, possibly due to increased susceptibility to 
degradation by cellular proteases (Chiang et al., 2004). The FAAH rs324420 has been 
extensively studied and has been associated with multiple phenotypes (Table 5). The 
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other 47 common SNPs locate either up- or downstream from the coding region or 
in introns. 
With regard to pain, FAAH -/- mice had a 50 to 100-fold decrease in hydrolysis of 
anandamide in their CNS. The mice exhibited reduced pain sensitivity, which could 
be reversed by a CB1 antagonist (Cravatt et al., 2001). Numerous FAAH inhibitors 
have been synthesized and in animal tests, they have shown promising results (Ahn 
et al., 2011; Li et al., 2012; Lichtman et al., 2004). One FAAH inhibitor BIA 10-2474 
was even subject to a phase I clinical trial on humans, although the trial had to be 
halted due to unexpected adverse events (Mallet et al., 2016).
One previous study has addressed FAAH polymorphisms and pain. This study showed 
association between three FAAH SNPs (rs932816, rs4141964 and rs2295633) and 
cold pain sensitivity. Rs4141964 was also shown to reduce cold withdrawal time by 
15% (Kim et al., 2006).




Cold pain No Kim 2006
Addiction
Problem drug use Positive Flanagan 2006, Sipe 2002




Marijuana craving Negative Haughey 2008
Happiness after marijuana smoking Negative Schacht 2009
Marijuana withdrawal symptom severity Negative Schacht 2009
Regular use of alcohol No Tyndale 2007
Risky alcohol consumption Negative Buhler 2014
Alcohol dependence No Tyndale 2007, Iwasaki 
2007
Regular use of nicotine No Tyndale 2007
Nicotine dependence No Tyndale 2007
Regular sedative use Negative Tyndale 2007
Sedative dependence No Tyndale 2007
Heroin addiction No Proudnikov 2010
Methamphetamine dependence Positive / no Sim 2013, Morita 2005
Arousal after amphetamine use Positive Dlugos 2010
Regular sedative use Positive Tyndale 2007
Regular stimulant use No Tyndale 2007
Opioid system
Opioid induced respiratory depression Positive Chidambaran 2017, 
Sadhasivam 2015







Threat related amygdala reactivity Negative Hariri 2009
Reward-related ventral striatal reactivity Positive Hariri 2009
Fronto-amygdala connection Positive Dincheva 2015
Mental health
Fear extinction Positive Dincheva 2015
Anxiety level (STAI) Negative Dincheva 2015
Anxiety response to stress Negative Spagnolo 2016
PTSD symptoms severity Negative Spagnolo 2016
Emotional-motivational reactivity Negative Conzelmann 2012
Anorexia nervosa Positive Monteleone 2009
Bulimia nervosa Positive Monteleone 2009
Binge eating disorder No Monteleone 2008
Antisocial personality disorder Positive Hoenicka 2007
Schizophrenia No Morita 2005
Bipolar disorder No Piscanu 2013
Body	composition	and	related	metabolic	effects
Obesity Positive (2) / 
no (4)
Sipe 2005, Monteleone 
2008, Jensen 2007, 
Papazoglou 2008, Lieb 
2009, Muller 2010
Hypocaloric	diet's	effect	on	insulin	levels Negative de Luis 2013
Prevalence of metabolic syndrome No de Luis 2012
 Antipsychotic drug associated weight gain No / Positive Nurmi 2013, Monteleone 
2010
Decrease in cholesterol and triglycerides 
after high polyunsaturated fat diet
Positive Aberle 2007, de Luis 
2013
High BMI Positive Zhang 2009, de Luis 
2010
Increased triglycerides Positive /
Negative 
Zhang 2009, de Luis 
2010
Level of HDL cholesterol Negative Zhang 2009
Insulin sensitivity No Zhang 2009
Waist circumference No De Luis 2010
Insulin level Positive De Luis 2012
Somatic health
Myocardial infarction Positive Chmelikova 2015
Irritable bowel syndrome No Jiang 2014
Functional gastrointestinal disorders Positive Camilleri 2008
Crohn’s disease symptom severity Positive Storr 2009
Earlier onset of ulcerative colitis Positive Storr 2009
Systolic blood pressure in young males Negative Sarzani 2008
Heart rate after marijuana smoking Positive Schacht 2008
Risk for acute respiratory distress syndrome Positive Tejera 2012
Pharmacological
Placebo	effect Positive Pecina 2014
Citalopram	treatment	efficacy No Mitjans 2012




Cytochrome P-450 3A is probably the most pharmacokinetically important enzyme 
in the metabolism of drugs as this protein participates in the metabolism of most of 
the drugs in clinical use (Burk et al., 2004). CYP3A and its isoenzymes CYP 3A4, 
3A5 and 3A7 are highly expressed in the small intestine and the liver. Lower rates of 
expression	can	be	found	in	several	other	tissues,	but	the	clinical	significance	of	this	
remains uncertain. 
CYP3A isoenzyme genes are all located next to each other in the long arm of chromosome 
7	and	around	60	known	polymorphisms	have	been	identified	in	the	gene	(NCBI	Gene	
Database: CYP3A4). Most of them are SNPs and have very low allelic frequencies, 
which	makes	 their	 effect	hard	 to	 study.	Of	 the	60,	only	 eight	polymorphisms	have	
shown to alter CYP3A4 function in vitro and two in vivo (Table 6). 
Investigations of CYP3A4*18A (rs28371759) by observing the concentration of 
midazolam have seemed to demonstrate an increase in the CYP3A4 activity when tested 
in vitro but a decreased activity when tested in vivo (Kang et al., 2009). CYP3A4*22 
(rs35599367) has been deemed the most clinically relevant polymorphism in the 
CYP3A4 gene as this polymorphism has been shown to reduce both CYP3A4 hepatic 
expression and enzyme activity by reducing the production of a functional full-length 
mRNA (Wang et al., 2011). CYP3A4*22 locates in an intron but seems to alter the 
splicing pattern of the mRNA (Wang et al., 2016). CYP3A4*22 carriers metabolize 
many	drugs	slower	than	wild-type	individuals	do	and	clinical	differences	have	been	
shown with statins, cyclosporine, midazolam and erythromycin (Wang et al., 2011; 
Elens et al., 2013). CYP3A4 enzyme activity can also be easily upregulated by many 
substrates, which can be endogenous, like corticosteroids or xenobiotics, such as 
phenytoin or rifampicin. 
CYP3A5 is expressed in the small intestine, liver, kidney and many other organs 
(NCBI Gene Database: CYP3A5). The relative amount of CYP3A5 in the total 
CYP3A pool varies greatly between individuals (Burk et al., 2004) and so far, the 
most	 influential	 polymorphism	 has	 been	 found	 to	 affect	 CYP3A5 expression is 
6986A>G (rs776746, CYP3A5*3). This polymorphism results in a cryptic splice site 
in the intron 3 of the CYP3A5 leading to premature termination of transcription and 
a shortened mRNA. The transcription product is usually quickly degraded (Kuehl 
et al., 2001). Nevertheless, some pre-mRNA molecules escape the altered splicing 
effect	resulting	in	completely	normal,	functional	mRNAs	(Lin	et	al.,	2002)	meaning	
that even individuals homozygous for the G-allele express some amount of CYP3A5. 
The	individual	effect	of	CYP3A5 polymorphism on drug metabolism is hard to study 
since the enzyme is always co-expressed with CYP3A4. Often both enzymes participate 





The	 effect	 of	CYP3A4/5 activity on oxycodone metabolism has been researched 
primarily by the co-administration of oxycodone together with a known CYP3A4/5 
inducer or inhibitor. Strong CYP3A4 inhibitors have been shown to increase 
oxycodone exposure by 200-300% (Hagelberg et al., 2009; Nieminen et al., 2010b). 
In contrast, when used together with a CYP3A4 inducer the oxycodone exposure 
decreased by 50-85% (Nieminen et al., 2009; Nieminen et al., 2010a). With regard to 
the	effect	of	CYP3A4/5 polymorphism on oxycodone metabolism, to date no studies 
have	been	performed,	however,	fentanyl	has	been	studied	concerning	the	effect	of	
CYP3A4*18. Of the three studies of this polymorphism and post-operative fentanyl 
consumption,	two	found	no	significant	change	in	the	dose	of	fentanyl	required	for	
analgesia (Tan et al., 2012; Kim et al., 2013). The other study however, did notice 
a	 statistically	 significant	 difference	 in	 fentanyl	 requirement	 between	CYP3A4*18 
homozygotes	and	wild-type	homozygotes	at	48h	after	the	operation	but	no	difference	
between heterozygotes or either homozygotes (Liao et al., 2013). One study has 
looked at CYP3A4*22’s	effect	to	fentanyl	plasma	concentrations	but	combined	this	
to multiple other phenotypes (Barratt et al., 2014) and consequently, no conclusions 
about	the	individual	effect	of	the	polymorphism	can	be	drawn.	
Table 6.	The	polymorphism	shown	to	affect	CYP3A4	activity	 in	vitro	or	 in	vivo.	Altered	





ReferencesIn vivo In vitro
CYP3A4*8 13908G>A Decr Eiselt et al, 2001
CYP3A4*11 21867C>T Decr Eiselt et al, 2001
Murayama et al., 2002
CYP3A4*12 21896C>T Decr Eiselt et al, 2001
CYP3A4*13 22026C>T Decr Eiselt et al, 2001
CYP3A4*16A 15603C>G Decr Lamba et al, 2002
Murayama et al., 2002
CYP3A4*16B 15603C>G; 
20230G>A
Decr Fukushima-Uesaka et al, 2004
Murayama et al., 2002
CYP3A4*17 15615T>C Decr Dai et al, 2001
CYP3A4*18A 20070T>C Decr Incr Dai et al, 2001
Kang et al., 2009
CYP3A4*22 15389C>T Decr. Wang et al., 2011
Elens et al., 2011a
Elens et al., 2011b
2.3.2.4 cYp2d6
CYP2D6 belongs to the same cytochrome P450 family as the CYP3A enzymes. 
CYP2D6 locates in chromosome 22 and consists of nine exons and eight introns (NCBI 
Gene Database: CYP2D6). The gene possesses much variation with multiple allelic 
reVieW oF liTerATUre
40
variants and at least 22 null-alleles, known to result in a non-functional protein (Zhou 
2009b). Therefore, there is a high variation in enzyme activity between individuals, 
which ranges from a complete lack of enzyme activity to ultra-rapid activity caused by 
copy number variants. Traditionally individuals have been divided into 4 groups based 
on their gene composition. Poor metabolizers (PM) possess two null-alleles resulting 
in complete lack of a functioning CYP2D6 enzyme. Intermediate metabolizers (IM) 
have a severely impaired but somewhat functional version of the enzyme and usually 
these individuals carry multiple alleles that decrease the enzyme activity. Extensive 
metabolizers (EM) have a normally functioning gene and these individuals compose 
the majority of the Caucasian population. In ultra-rapid metabolizers (UM), there 
is multiple copies of the gene, resulting in a highly increased expression of the 
enzyme	 and	 enzyme	 activity.	 Recently,	 the	 classical	 4-step	 classification	 has	 been	
replaced with a continuous variable: the CYP2D6 activity score. The activity score 
predicts the CYP2D6 activity with more precision and is more easily interpreted and 
modified	to	meet	special	needs	(Gaedigk	et	al.,	2008).	In	the	activity	score	method,	
each	polymorphism	is	assigned	a	value	that	represents	the	polymorphisms	effect	on	
enzyme activity. The activity score is the calculated by summing up the values of the 
individual’s alleles. The values given to each polymorphism are listed in Table 7.
Table 7. Values assigned to CYP2D6 alleles in the activity score method. Each allele is given 
a	number	representing	its	effect	on	the	enzymes	activity.	Then	the	values	of	the	two	alleles	
are summed to form the activity score of the pair. N represents the number of duplication 
polymorhisms.	Modified	from	the	original	article	by	Gaedick	et	al.	(Gaedigk	et	al.,	2008).
Value assigned to allele Alleles
0 *3, *4, *4xN, *5, *6, *7, *16, *36, *40, *42, *56B
0.5 *9, *10, *17, *29, *41, *45, *46
1 *1, *2, *35, *43, *45xN
2 *1xN, *2xN, *35xN
Since CYP2D6 is responsible for the metabolism of many clinically used drugs such 
as antiarrhythmics, selective serotonin reuptake inhibitors, opioids, neuroleptics 
and anticancer agents, the high variation in enzyme activity causes problems that 
possibly	expose	the	patient	to	life-threatening	adverse	effects.	As	a	result,	CYP2D6	
has been extensively investigated and Zhou et al. (Zhou 2009a; Zhou 2009b) have 
compiled the results of CYP2D6	 polymorphism	 effects	 on	 different	 drugs	 in	 two	
extensive publications.
With regard to oxycodone analgesia, CYP2D6 metabolism seems to have no clinically 
significant	effect.	Although	it	has	been	suggested	that	oxymorphone	contributes	to	
oxycodone analgesia, the amount of oxymorphone produced by CYP2D6 remains 
too	low	for	any	significant	effect	(Lemberg	et	al.,	2009).	The	only	study	on	post-
operative	analgesia	found	no	significant	association	between	CYP2D6 genotype and 
post-operative oxycodone requirements (Zwisler et al., 2010).
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3. AIMS OF THE STUDY
The	 main	 purpose	 of	 this	 study	 was	 to	 identify	 factors	 affecting	 post-operative	
analgesia that could help anaesthesiologists and surgeons to recognise patients at risk 
of severe post-operative pain and high requirement of opioid analgesics, oxycodone 
as an example. 
The	specific	aims	of	this	thesis	were:
I.	 To	 define	 specific	 patient-dependent	 (demographic,	 clinical),	 genetic	
(OPRM1, FAAH, CYP3A4/5 and CYP2D6)) and surgery-dependent factors 
affecting	 post-operative	 oxycodone	 requirements	 and	 analgesic	 oxycodone	
concentrations	after	breast	cancer	surgery	and	to	estimate	their	effects.
II.	 To	define	specific	patient-dependent	(demographic,	clinical),	genetic	(OPRM1 
and FAAH)	 and	 surgery-dependent	 factors	 affecting	 post-operative	 pain	
intensity	after	breast	cancer	surgery	and	to	estimate	their	effects.
III.	 To	 define	 specific	 patient-dependent	 (demographic,	 clinical)	 and	 genetic	
(OPRM1 and FAAH))	 factors	 affecting	 experimental	 pain	 sensitivity	 and	
whether these factors associate with post-operative pain intensity.
MATeriAlS And MeTHodS
42
4. MATERIALS AND METHODS
4.1 Ethical considerations
The study protocol was approved by the coordinating ethics committee (136/
E0/2006) and the ethics committee of the Department of Surgery (Dnro 148/E0/05) 
of the hospital district of Helsinki and Uusimaa prior to the commencement of the 
study. All patients volunteered for the study and were informed of both the study 
procedure and any possible risks. Each patient provided a written informed consent, 
which was collected and archived by the research nurse or physician. The patients 
were free to withdraw from the study at any time.
4.2 Study subjects
The patients were recruited from the Breast Surgery Unit of the Helsinki University 
Central Hospital between August 2006 and December 2010. The inclusion criteria 
comprised of the following: a female patient diagnosed with unilateral, non-
metastasized breast cancer, aged 18-75 years. All patients were to undergo either 
breast conserving surgery (BCS) or mastectomy with sentinel node biopsy or axillary 
clearance. Exclusion criteria included metastasized cancer (other than axillary 
lymph	nodes),	clinically	significant	 liver	or	kidney	failure,	previous	breast	cancer	
surgery on the same side, BMI >35 (from the patient number 100 on), alcoholism, 
contraindications for use of oxycodone, and severe psychiatric disease. Additionally, 
patients undergoing immediate breast reconstruction were also excluded from the 
study. The type of surgery used was decided based on the characteristics of the 
tumour and according to the patient’s wishes.
During the recruitment period, there were 1,536 eligible patients of whom 387 were 
excluded due to logistic reasons. Of the 1,149 patients invited, 126 declined and 
23 were withdrawn due to contraindications to the anaesthetic protocol, change in 
the	type	of	surgery,	violation	of	the	study	protocol	or	due	logistic	reasons.	The	final	
cohort consisted of 1,000 women (Figure 7).
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Figure 7. Flowcharts of A. Patient selection and genotyping and B. Study procedures.
4.3 Study protocol
The day prior to surgery, each patient met with the research nurse in order to collect 
her background data. This included medical information and demographic background 
data: age, weight and height, diagnoses, medications, number of previous operations 
(other than breast surgery), previous chronic pain of any kind, preoperative use of 
hormonal replacement therapy, use of alcohol (no/less than six doses per week/more 
than six doses per week), alcohol problems in the family (no/yes) and smoking (never/
yes/stopped). Since all study patients were quite healthy (ASA grade 1 or 2), the 
patients were not automatically subjected to laboratory testing before surgery. Thus, no 
consistent data of liver or kidney function at the time of the operation were available. 
The patients were asked to assess the preoperative pain in the area to be operated 
on using a numerical rating scale 0-10 (NRS 0-10) zero indicating no pain and 10 
indicating	 the	 worst	 pain	 imaginable.	 Finally,	 all	 patients	 filled	 in	 psychological	
questionnaires to assess levels of depressive mood and anxiety. The questionnaires 
used included the Becks Depression Inventory (BDI) (Beck et al., 1961) and 
Spielberger State-Trait Anxiety Inventory (STAI) (Spielberger et al., 1983). STAI 
consist of 20 questions about anxiety which are given a 4-point frequency scale. 
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Patient can estimate, how often he/she experiences these feelings. Minimum score 
is 20 correlating to low anxiety, and maximum score 80 correlating to high anxiety. 
BDI consist of 21 questions with four answer oprtions. Patient chooses which one 
best descipes his/her state. Answers are rated on a 0-3 point scale. Total score of 0-9 
indicates minimal depression, 10-18 mild depression, 12-29 moderate depression 
and 30-63 severe depression. 
4.3.1 Experimental pain test
On the day before surgery, patients underwent two experimental pain tests for heat 
and cold pain. A careful explanation of these tests was performed with every patient 
beforehand. 
Heat pain assessment was carried out using the 16 mm x 16 mm thermode of the 
TSA-II NeuroSensory Analyzer (Medoc Ltd., Ramat Yishai, Israel) by placing it 
on	the	patient’s	hand’s	volar	side	contralateral	 to	 the	surgery.	In	the	first	step,	 the	
thermode was heated to 43°c for 5 seconds and the patient was asked to report the 
unpleasantness of the sensation using NRS 0-10. In the next step, the thermode was 
heated to 48°C and placed on the same area for 5 seconds. Again, the patient was 
asked to assess the unpleasantness of the sensation using NRS 0-10.
In the cold pain test the patient was asked to immerse her hand into a cold water bath 
at between 2-4°C (JULABO USA Inc., Allentown, PA, USA) and keep it there for 
the	maximum	time	that	could	be	tolerated	with	a	cut-off	time	of	90	seconds.	Pain	
intensity and unpleasantness was recorded every 15 seconds using an NRS 0-10 and 
the	NRS	score	was	also	recorded	at	the	time	of	hand	withdrawal.	For	the	first	100	
patients this cold pain test was not conducted due to the unavailability of the cold-
water bath device. 
4.3.2 Anaesthesia
The anaesthetic procedures were standardised - patients were pre-medicated 
with diazepam 2.5 – 15 mg and 1g acetaminophen. In the operating theatre, an 
intravenous (i.v.) infusion of remifentanil (0.05-0.25 µg·kg-1·min.1) was started. 
Anaesthesia was induced and maintained with i.v. propofol (2-3 mg·kg-1 and 50-
100 µg·kg-1·min-1).	 Rocuronium	 was	 administered	 to	 achieve	 sufficient	 muscle	
relaxation for the tracheal intubation and to keep the train-of-four at 0-10% 
(E-NMT: General Electrics Healthcare Finland, Helsinki, Finland). Mechanical 
ventilation was adjusted with a 1:1 mixture of oxygen and nitrous oxide to keep 
normocapnia. During the closure of the skin, the remifentanil infusion was stopped, 
and patients were given i.v. fentanyl (0.1 µg·kg-1), i.v. ondansetron 4mg and i.v. 
droperidol (0.01 mg·kg-1). Before moving the patient to the post-anaesthesia care 
unit (PACU), the neuromuscular block was reversed using i.v. neostigmine 2.5mg 
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and i.v. glycopyrrolate 0.5mg. At this point, the intubation tube was removed and 
a blood sample for DNA analyses was drawn during the anaesthesia to minimize 
the need for punctures. 
4.3.3 Postoperative pain assessment and administration of oxycodone
In the PACU, patients were asked to assess their pain intensity during rest and 
motion using NRS 0-10. For the motion pain assessment, the patient was asked to 
raise the arm ipsilateral to surgery up to 90 degrees. The patient was then titrated to 
satisfactory anaesthesia (NRS 0-10 < 4) by the research nurse who asked about the 
pain intensity every 5 min and administered 1-3mg i.v. oxycodone accordingly. Once 
the patient reported NRS < 4 or indicated otherwise satisfaction with the anaesthesia, 
a blood sample was taken for the plasma oxycodone concentration measurement. 
The research nurse continued monitoring the anaesthesia by asking the patient to 
rate pain intensity every 15 min. When the patient needed a new dose of oxycodone, 
a second blood specimen was collected for the oxycodone plasma concentration 
measurement prior to the administration of a new oxycodone dose. 
Analgesic concentration in this study refers to the plasma concentration at which the 
patient	felt	that	the	effect	of	the	drug	was	satisfactory	(provided	adequate	analgesia).	
No therapeutic range or analgesic concentration for oxycodone or other opioids has 
been	specified.
After approximately 2 hours in the PACU, patients were provided with patient-
controlled analgesia devices (PCA) (Abbott Laboratories, North Chicago, IL, or 
CADD-LegacyT: Deltec, Inc., St. Paul, MN), the research nurse explained their use 
and the patients were transferred to the ward. PCA oxycodone was available for 
up to 20h except for the 70 day-surgery patients who were discharged during the 
operation day. The patient self-administered i.v. oxycodone from the PCA in 1 -3.5 
mg boluses with an 8 - 10 min lock-out time. The total oxycodone consumption 
and	 any	 adverse	 effects	 during	 the	 first	 20	 post-operative	 hours	were	 recorded.	
All patients were also provided with 1g of paracetamol as basic analgesic every 8 
hours.
4.4 SNP selection
Originally eight genes (OPRD1, OPRM1, FAAH, ABCB1, TRPA1, TRPV1, GCH1, 
COMT) were selected as primary candidate genes for pain perception and relief 
on	the	basis	of	the	findings	from	previous	studies	(Kim	et	al.,	2006;	Campa	et	al.,	
2008; Diatchenko et al., 2005; Tegeder et al., 2006). One or several functional or 
reported candidate SNPs was/were selected from each of these prioritized genes 
and multiplexed in order to be genotyped by Sequenom MassArray. Altogether, 22 
SNPs were genotyped. This Sequenom-generated dataset also contained the OPRM1 
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rs1799971 SNP and two SNPs (rs3766246 and rs4141964) located within the FAAH 
gene. The OPRM1 and FAAH genes were selected for a more thorough investigation 
because of the promising results with these two SNPs in preliminary analyses and 
results from previous studies.
In study I addressing oxycodone and metabolite concentrations, one SNP from 
CYP3A4 and CYP3A5 were included in the analysis. CYP3A4/5 is the main 
metabolizer of oxycodone. The two SNPs CYP3A4 rs35599367 (*22) and 
CYP3A5	 rs776746	 (*3)	 were	 selected	 since	 both	 have	 been	 shown	 to	 affect	 the	
pharmacokinetics and drug response of many drugs (Wang et al. 2011; Elens et al. 
2011 a & b; Jacobson et al., 2011).
4.5 Genotyping
DNA was extracted from the peripheral blood of 996 patients using the Autopure LS 
automated	DNA	purification	 instrument	 (Gentra	Systems,	 Inc.,	Minneapolis,	MN,	
USA).  
Genotyping of the 22 candidate SNPs was performed at the Institute for Molecular 
Medicine Finland FIMM Technology Centre at the University of Helsinki (Helsinki, 
Finland). The SNPs were genotyped using the MassARRAYsystem and iPLEX Gold 
Single Base Extension chemistry (Sequenom, San Diego, CA, USA). Both duplicate 
and	positive-negative	control	samples	were	included	in	each	plate	in	order	to	confirm	
the accuracy of the genotyping results. This set included OPRM1 rs1799971 and 
FAAH rs3766246 and rs4141964.
Patients were genotyped for 10 CYP2D6 SNPs and copy number variation using 
Taqman genotyping assays and a copy number assay targeting exon 9 (Pietarinen 
et al., 2016). CYP2D6 metabolizer groups were inferred from the genotype data 
using the activity score method (Gaedigk et al., 2008). Both CYP3A4 rs35599367 
(*22) and CYP3A5 rs776746 were genotyped using Taqman genotyping assay 
(ThermoFisher	 Scientific,	Waltham,	MA,	USA),	CYP3A4 rs35599367 (*22) with 
a commercially available kit (C_59013445_10) and CYP3A5 rs776746 (*3) with a 
custom genotyping assay. 
The GWA genotype data were produced at the Wellcome Trust Sanger Institute 
(Hinxton, UK) on the Human OmniExpress Illumina BeadChip (Illumina, Inc., San 
Diego, CA, USA) and were blind to phenotypic information. Of the 996 samples, 
genotyping of 47 failed due to the low quality of the DNA or other technical issues. 
The quality control procedure of the remaining 949 samples consisted of checking 
the data for heterozygosity (14 fails), unexpected relatedness (5 fails) and creating 
multidimensional scaling plots (4 genetic outliers rejected based on dimensions 
9-10).	 The	 SNPs	 were	 filtered	 based	 on	 minor	 allele	 frequency	 (MAF	 >0.005),	
Hardy-Weinberg equilibrium (HWE p >1x10-6) and success rate (>0.97). After these 
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exclusions,	 the	final	 cohort	 consisted	of	926	 individuals	with	 a	mean	genotyping	
success rate of 0.997 (Figure 7). 
OPRM1 rs1799971 genotype data was extracted from candidate SNP data genotyped 
using the MassArray platform. The other 20 OPRM1 SPNs were extracted from the 
GWAS data located within the surrounding 20 kb area of the gene (chr6: 154380 – 
154476 kb, NCBI36/hg18). 
In Study II that focused on FAAH, the genotype data was extracted from the GWA 
data. In the GWA dataset, eight SNPs were located within the FAAH gene or the 
surrounding 20 kb area (chr1: 46,612 – 46,672 kb, NCBI36/hg18). Prior to the 
availability of the GWA data, two candidate SNPs (rs4141964 and rs3766246) were 
genotyped with the MassArray platform. As a result, SNP rs3766246 was available 
in both the candidate SNP and GWA data.
4.6 Measurement of oxycodone and its metabolites
Plasma	 concentrations	 of	 oxycodone	 and	 three	 of	 its	metabolites	were	 quantified	
from 0.5 ml plasma samples using an API 3000 liquid chromatography-tandem 
mass-spectrometry system (Sciex Division of MDS, Toronto, Ontario, Canada) 
as described previously (Neuvonen M et al., 2008). The method was validated 
according to the Food and Drug Administration guidelines. (FDA Guidance, CDER, 
US Department of Health and Human Services, Food and Drug Administration, 
Center for Drug Evaluation and Research and Center for Veterinary Medicine 
(CVM): Guidance for the Industry, Bioanalytical Method Validation, May 2001). The 
lower	limits	of	quantification	for	oxycodone	and	oxymorphone	and	noroxycodone	
and noroxymorphone were 0.1 ng/mL and 0.25 ng/mL, respectively. The inter-day 
coefficient	 of	 variation	 for	 all	 analytes	 at	 the	 relevant	 concentrations	was	 below	
15%.	Oxycodone	and	its	metabolite	concentrations	below	the	limit	of	quantification	
were	 replaced	with	half	of	 the	quantification	 limit,	 except	 for	 those	patients	who	
did not need any oxycodone and were thus excluded from the respective analyses. 




Power calculations for OPRM1 rs1799971 and FAAH SNPs were conducted 
using the freely available Quanto software, version 1.2.4 (University of Southern 
California	 2009).	 This	 software	 was	 used	 to	 estimate	 the	 effect	 sizes	 that	 the	




in FAAH SNPs was considered by performing power calculations for the most and 
least frequent SNPs. 
4.7.2 Defining factors affecting postoperative motion pain intensity, 
oxycodone dose required for satisfactory analgesia and oxycodone 
concentration at satisfactory analgesia.
In	 Study	 I,	 the	 possible	 effects	 of	 the	 variables	 affecting	 plasma	 oxycodone	
concentrations were investigated using a stepwise, forward linear regression analysis 
using SPSS Statistics version 22 (IBM, Armonk, NY). The same method was used 
for the determination of factors associating with experimental cold pain intensity at 
30s, post-operative pain intensity and post-operative oxycodone dose requirements. 
A	statistical	significance	level	of	P < 0.05 for entry into the model and > 0.10 for 
removal was set. Motion pain intensities, oxycodone doses and oxycodone plasma 
concentrations did not follow normal distribution, so they were logarithmically 
transformed before statistical analysis. The factors included in the linear regression 
for each analysis are given in Table 8 and 9.
Possible	 effects	 of	 CYP2D6 genotypes on oxycodone metabolite concentrations 
were	investigated	with	one-way	analysis	of	variance	as	were	the	differences	between	
postoperative pain intensity groups. Oxycodone and metabolite concentrations did 
not follow normal distribution, so they were logarithmically transformed before 
analysis.
Table 8. Factors tested in the linear regression analysis for cold pain intensity at 30s. BMI 
=body mass index, NRS = numerical rating scale, STAI = State-Trait Anxiety Inventory





Preoperative chronic pain (yes/no)






Table 9. The factors tested in the linear regression analysis for each postoperative primary 
phenotype. BMI =body mass index, NRS = numerical rating scale, STAI = State-Trait 
Anxiety Inventory, BCS = breast conserving surgery, SNB = sentinel node biopsy, AC = 
axillary clearance
Motion pain intensity Postoperative oxycodone 




required for satisfactory 
analgesia
Age (year) Age (year) Age (year)
Weight (kg) Weight (kg) Weight (kg)
BMI (kg m-2) BMI (kg m-2) BMI (kg m-2)
Smoking (yes/no) Smoking (yes/no) Smoking (yes/no)
Preoperative chronic pain (yes/
no)
Preoperative chronic pain (yes/
no)
Preoperative chronic pain (yes/
no)
Preoperative breast pain (NRS 
0-10)
Preoperative breast pain (NRS 
0-10)
Preoperative breast pain (NRS 
0-10)
Anxiety (STAI) Anxiety (STAI) Anxiety (STAI)
Cold pain intensity at 30s 
(NRS 0-10)
Cold pain intensity at 30s 
(NRS 0-10)
Cold pain intensity at 30s 
(NRS 0-10)
The total time patients kept 
their hand immersed in cold 
water (s)
The total time patients kept 
their hand immersed in cold 
water (s)
The total time patients kept 
their hand immersed in cold 
water (s)
Heat pain intensity (NRS 0-10) Heat pain intensity (NRS 0-10) Heat pain intensity (NRS 0-10)
OPRM1 rs1799971 genotype OPRM1 rs1799971 genotype OPRM1 rs1799971 genotype
FAAH rs324420 genotype FAAH rs324420 genotype Mastectomy (vr. BCS)
Mastectomy (vs. BCS) Mastectomy (vs. BCS) Axillary clearance (vs. SNB)
Axillary clearance (vs. SNB) Axillary clearance (vs. SNB) Motion pain (NRS 0-10)
Motion pain (NRS 0-10) Resting pain (NRS 0-10)
Resting pain (NRS 0-10) CYP2D6 genoype
CYP2D6 genoype CYP3A4 rs355367 genotype
CYP3A4 rs355367 genotype CYP3A5 rs776746 genotype
CYP3A5 rs776746 genotype Lean body weight (kg)
4.7.3 Genetic association studies (studies II and III)
OPRM1 and FAAH	 polymorphisms	 were	 assessed	 for	 statistically	 significant	
deviations from the Hardy-Weinberg equilibrium using the X2 method with Plink 
software (Purcell et al., 2007).
Associations between OPRM1 and FAAH with clinical phenotypes were obtained 
using	linear	regression.	Additive,	recessive	and	dominant	models	were	used	to	find	
association with genotype and phenotype data. Since all phenotypic data were not 
normally distributed, associations were also assessed through permutation testing. 
Each	model	was	fitted	10.000	times	and	the	original	statistics	were	compared	with	
the test statistics received from permutation.
MATeriAlS And MeTHodS
50
All association results were corrected using Bonferroni correction to compensate for 
the increased chance of rare events caused by the multiple testing. The number of 
tests was set to the number of phenotypes, SNPs and models used. For the 8 FAAH 
SNPs the correction factor was set to 6.2 due to the strong linkage disequilibrium 
between the SNPs.
For the FAAH SNPs haplotype analyses were conducted. Haploblock boundaries 
and linkage disequilibrium between the SNPs were determined using Haploview 
software (version 4.2). The haplotype analyses were conducted using Plink software 




5.1 Characteristics of the patients
The	 final	 study	 cohort	 consisted	 of	 1,000	 women	 undergoing	 surgery	 for	 breast	
cancer. The demographics of the patients are presented in Table 10. 420 patients 
underwent breast conserving surgery with sentinel node biopsy and 206 breast 
conserving surgery with axillary clearance. Mastectomy was performed on 374 
patients, of whom, 140 had sentinel node biopsy and 234 axillary clearance. 
Table 10. The means (SD) of demographic factors in the study population. Number of 
smokers are given as individuals. STAI = State-Trait Anxiety Inventory, NRS = numerical 
rating scale.
Age (years) 57.0 (9.28)
Height (cm) 165 (5.97)
Weight (kg) 69.1 (12.1)
BMI 25.4 (4.28)
Anxiety score (STAI) 40.3 (11.2)
Preoperative breast pain (NRS) 1.14 (3.41)
Preoperative chronic pain (%) 24.20%
Smoking (never/yes/stopped/periodic) 591/167/228/14
5.2 Genotypes of the patients
With regard to OPRM1 genotype the study population consisted of 631 AA, 327 AG 
and	35	GG	individuals.	The	three-genotype	groups	did	not	differ	significantly	for	the	
studied demographics. The FAAH genotype frequencies are shown in Table 11 and 
the combined OPRM1 and FAAH genotypes in Table 12.
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Table 11. The genotype counts and minor allele frequencies of the studied FAAH 
polymorphisms. SNP = single nucleotide polymorphism, MM = major allele homozygotes, 







HWE pMM Mm mm
rs3863641 A > G 0.38 364 415 144 0.13
rs3766246 G > A 0.38 347 448 128 0.4
rs324420 C > A 0.28 469 380 72 0.75
rs11576941 C > A 0.27 481 373 66 0.62
rs324425 G > A 0.03 865 57 1 1
rs4660928 C > A 0.35 386 422 115 1
rs1571138 G > A 0.28 475 376 72 0.94
rs1535737 G > A 0.35 382 433 108 0.43
Table 12. The counts of pairwise combinations of OPRM1 rs1799971 and FAAH rs324420 
genotypes.
rs1799971
rs324420 AA AG GG Total
CC 301 158 13 472
AC 234 125 21 380
AA 48 24 0 72
Total 583 307 34 924
Table 13. The genotype counts and minor allele frequencies of CYP3A4 rs355367 and 
CYP3A5 rs776746
SNP ID Nucleotide change
Minor allele 
frequency
Genotype count HWE pMM Mm mm
rs355367 C>T 0.03 885 45 1 0.58
rs776746 G>A 0.08 792 135 3 0.21
5.3 Experimental cold pain
Cold pain intensities were available from 900 of the study patients. Patients held 
their hand in the cold water for an average of 46.4 (29.5) seconds. The average NRS 
at the time of withdrawal was 8.3 (1.8). For further analysis, the time point 30s was 
chosen because at 30s the mean pain intensity was already high, but the majority 
(60%) of patients still kept their hand in the water (Table 14). 
Table 14. Number of patients who kept their hand immersed in the cold water and their 
average cold pain intensities. 
15 s 30 s 45 s 60 s 75 s 90 s
Patients (n) 780 545 386 295 238 214
NRS 0 - 10 5.0 (2.5) 6.31 (2.4) 7.1 (2.4) 7.6 (2.3) 7.8 (2.3) 8.0 (2.2)
reSUlTS
53
5.3.1 Associations between cold pain and other phenotypes
The cold pain intensity at 30 s, the total time patients kept their hand immersed or 
heat pain did not associate with post-operative oxycodone plasma concentrations 
required for analgesia in the linear regression (Study I) (P=0.20 and P=0.34). 
Nevertheless, cold pain intensity and the total time patients kept their hand in the 
cold	water	showed	a	significant	association	with	post-operative	motion	pain	intensity	
(Table 15).
5.3.2 Factors affecting cold pain intensity
Factors	affecting	experimental	cold	pain	intensity	at	30s	were	the	patient’s	anxiety	
level, age and FAAH rs324420 genotype. Each STAI score increased cold pain 
intensity by 0.46%, while each age year reduced it by 0.48%. Each FAAH rs324420 
A-allele reduced cold pain intensity by 8.4% (Table 15).
Table 15. The factors associating with experimental cold pain intensity at 30s. Results were 
obtained using forward type linear regression. Excluded variables are phenotypes tested 
but	determined	insignificant.	R	square	(coefficient	of	determination)	for	the	model	is	0.038.	 
Beta	=	standardized	coefficients	for	model,	B	=	Increase	in	experimental	cold	pain	intensity,	
STAI = State-Trait Anxiety Inventory, BMI = Body Mass Index, NRS = Numerical Rating 
Scale (0-10). 
 Confidence interval 95%
Variable B Lower Upper P
Anxiety (STAI) 0.46% 0.08% 0.84% 0.018
FAAH rs324420 genotype 8.40% 1.90% 15.30% 0.011
Age (years) -0.48% -0.90% -0.05% 0.028
Excluded variables Beta P
Weight (kg) -4.80%   0.280
BMI (kg m-2) 1.30% 0.779
Preoperative chronic pain (yes/no) 2.30% 0.603
Smoking (yes/no) -5.60%   0.198
Preoperative breast pain (NRS 0-10) 3.70%   0.435
OPRM1 rs1799971 genotype 4.10%   0.377
5.3.3 Genetic associations with experimental cold pain
OPRM1 rs1799971 genotype did not associate with cold pain intensity at any studied 
time point or with the total time patients kept their hand immersed in the water (Study 




Figure 9. Cold pain intensity by OPRM1	rs1799971	genotype	at	different	time	points
Of the eight studied FAAH SNPs, four showed associations with cold pain intensity at 
30 s (uncorrected p <0.05). Only two associations survived the Bonferroni correction 
for multiple testing (corrected p = 0.0014). The SNPs rs324420 and rs1571138 were 
in almost complete linkage disequilibrium (98%). Patients homozygous for the 
minor allele A of the rs324420 or rs1571138 reported - on average - 1.43 NRS points 
lower cold pain intensities than patients who were heterozygous or homozygous for 
the major alleles (Study III)(Figure 10). 
Figure 10. Cold pain intensity by FAAH	rs324420	genotype	at	different	time	points	
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5.4 Experimental heat pain
Most patients did not consider the sensation caused by the 43°C temperature as painful 
(mean NRS 0.7). The mean NRS score for heat pain intensity with 48°C temperature 
for 5 seconds was 3.5 (SD 2.4) of which 95 patients did not regard the sensation as 
painful; 462 reported mild pain (NRS 1-3); 351 moderate pain (NRS 4-7) and 79 
severe pain (NRS 8-10). Heat pain scores were not available for 13 patients (Figure 8). 
Figure 8. Pain intensities (x-axis) reported by the patient to control (43°C) and heat (48°C) 
stimulation. Number of patients given on y-axis. 
5.4.1 Associations between experimental heat pain and other phenotypes
Experimental heat pain did not associate with post-operative motion pain intensity 
or analgesic oxycodone dose.
5.4.2 Genetic associations with heat pain
Neither OPRM1 rs1799971, nor any of the studied FAAH SNPs, associated with heat 
pain intensity at either of the temperatures (Studies II and III). When looking at all 
the SNPs of OPRM1, there were two nominal associations to heat pain intensity: 
Rs3778153 associated with heat pain when the additive model was used (uncorrected 
p= 0.043) and rs4870266, when the recessive model was used (uncorrected p= 0.019) 
for analysis. Neither of the associations remained after corrections for multiple 
testing. 
5.5 Post-operative pain
In the PACU, both rest and motion pain intensities were assessed in all patients 
before any oxycodone was administered. Pain intensity at rest and in motion 
correlated almost completely (r = 0.99, P <0.001). Nine patients reported no rest 
pain (NRS 0); 63 mild rest pain (NRS 1-3); 817 moderate rest pain (NRS 4-7) and 68 
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severe rest pain (NRS 8-10). Rest pain scores were unavailable for 43 patients. The 
mean rest pain score was 4.95 (1.47), whereas the mean motion pain score was 4.99 
(1.48). Seven patients reported no motion pain, 60 mild motion pain, 815 moderate 
motion pain and 67 severe motion pain. Motion pain scores were unavailable from 
51 patients.
5.5.1 Factors associating with postoperative pain intensity
When looking at factors that explain post-operative motion pain intensity, age 
was determined to be the most important factor with every age year lowering the 
pain	 intensity	 score	 by	 0.51%.	 Other	 significant	 factors	 were	 axillary	 clearance,	
preoperative cold pain intensity at 30s and cold pain tolerance. Together these factors 
explained 8.5% of the variability in the motion pain intensities (Table 15).
OPRM1 rs1799971 genotype did not associate with post-operative motion pain 
intensity when assessed individually (Study II) or when combined with other 
variables. FAAH	 did	 not	 associate	 significantly	 with	 post-operative	 motion	 pain	
intensity.
Table 15. Factors associating with post-operative motion pain intensity. Results were 
obtained using forward type linear regression. Excluded variables are phenotypes tested but 
determined	insignificant.	R	square	(coefficient	of	determination)	for	the	model	is	0.085	Beta	=	
standardized	coefficients	for	model,	B	=	Increase	in	postoperative	motion	pain	intensity,	SNB	
= Sentinel Node Biopsy, STAI = State-Trait Anxiety Inventory, BCS = Breast conserving 
surgery, BMI = Body Mass Index, NRS = Numerical Rating Scale (0-10). 
Confidence interval 95%
Variable B Lower Upper P
Age (years) -0.51% -0.75% -0.28% <0.001
Axillary clearance (vs. SNB) 5.18% 1.83% 8.63% 0.002
Cold pain intensity at 30s (NRS 0-10) 1.83% 0.67% 3.00% 0.002
The total time patients kept their hand 
immersed in cold water (s)
0.13% 0.02% 0.24% 0.024
Excluded variables Beta P
Weight (kg) -0.10% 0.983
BMI (kg m-2) -0.30% 0.954
Anxiety (STAI) 5.23% 0.259
Preoperative chronic pain (yes/no) 6.18% 0.182
Smoking (yes/no) 6.18% 0.174
Heat pain intensity (NRS 0-10) 4.81% 0.333
Preoperative breast pain (NRS 0-10) 4.50% 0.34
Mastectomy (vs. BCS) 2.47% 0.592
OPRM1 rs1799971 genotype -3.53% 0.421
FAAH rs324420 genotype -5.45% 0.208
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5.6 Post-operative oxycodone requirements
Altogether 47 patients did not require any oxycodone in the PACU. Of these, 31 
patients	 did	 not	 require	 oxycodone	during	 the	first	 20	 postoperative	 hours.	On	
average,	 the	 patients	 required	 0.13	 mg/kg	 of	 oxycodone	 to	 feel	 satisfied	 with	
pain	relief	and	a	total	of	0.25	mg/kg	during	the	first	20	postoperative	hours.	The	
time it took the patients to reach satisfactory analgesia varied from 11 to 132 
minutes	(mean	38.3	min).	The	time	the	patients	remained	satisfied	after	the	first	
state of satisfactory analgesia varied from 10 to 1106 minutes (mean 161 min). 
The	 399	 patients,	 who	 did	 not	 require	more	 oxycodone	 after	 the	 first	 state	 of	
satisfactory analgesia in the PACU, were older and less anxious compared with 




5.6.1 Genetic association with postoperative oxycodone requirements
OPRM1	rs1799971	associated	with	the	oxycodone	dose	required	for	the	first	state	
of satisfactory analgesia. The patients homozygous for the minor allele required 
on average 0.04 mg/kg more oxycodone to achieve analgesia than the major allele 
homozygotes	 (Study	 II).	No	difference	between	 the	genotype	groups	was	 seen	at	
the total oxycodone consumption during the 20 postoperative hours. FAAH SNPs 
rs3863641, rs3766246, rs324420 and rs1571138 showed nominal associations 
(uncorrected	 p<0.05)	 with	 the	 oxycodone	 dose	 required	 for	 the	 first	 state	 of	
satisfactory	analgesia	and	with	the	total	oxycodone	consumption	during	the	first	20	
postoperative hours. However, these associations did not survive the corrections for 
multiple testing (Study III, supplementary material).
5.6.2 Factors explaining post-operative oxycodone requirements
Factors that associate with post-operative oxycodone dose requirement were motion 
pain intensity before patient was administered oxycodone, BMI, surgery type 
(axillary clearance vs. sentinel node biopsy), age, OPRM1 genotype and the intensity 
of preoperative breast pain (Figure 11). Every motion pain NRS point increased the 
oxycodone dose requirement by 23%. Similarly, patients who underwent axillary 
clearance or had preoperative breast pain required higher oxycodone doses. Each 
OPRM1 rs1799971 G allele increased the required post-operative oxycodone dose 




Table 16. Factors associating with the oxycodone dose required for the 1st state of satisfactory 
analgesia. Results were obtained using forward type linear regression. Excluded variables are 
phenotypes	 tested	but	determined	insignificant.	R	square	for	 the	model	 is	0.286	R	Square	
=	coefficient	of	determination,	Beta	=	standardized	coefficients	for	model,	B	=	Increase	in	
oxycodone dose needed for satisfactory analgesia, SNB = Sentinel Node Biopsy, STAI = 
State-Trait Anxiety Inventory, BCS = breast conserving surgery, BMI = Body Mass Index, 
NRS = Numerical Rating Scale (0-10). * CYP2D6 genotypes include ultra-rapid, extensive, 
intermediate and poor metabolizers
Confidence interval 95%
Variable B Lower Upper P
Motion pain (NRS 0-10) 23.10% 18.10% 28.40% <0.001
BMI (kg m-2) -2.52% -3.77% -1.26% <0.001
Axillary clearance (vs. SNB) 12.80% 4.02% 22.40% 0.004
Age (years) -0.78% -1.38% -0.18% 0.011
OPRM1 rs1799971 genotype 10.70% 1.75% 18.80% 0.02
Preoperative breast pain (NRS 0-10) 5.21% 0.78% 9.83% 0.021
Excluded variables Beta P
Weight (kg) -5.91% 0.524
Preoperative chronic pain (no/yes) 0.10% 0.977
Anxiety (STAI) 5.65% 0.172
Smoking (no/yes) 0.10% 0.976
Cold pain intensity at 30s (NRS 0-10) 3.45% 0.405
The total time patients kept their hand 
immersed in cold water (s)
-3.34% 0.402
Heat pain (NRS 0-10) 4.50% 0.271
Mastectomy (vs. BCS) 6.18% 0.165
Resting pain (NRS 0-10) 36.60% 0.247
FAAH rs324420 genotype 2.02% 0.612
CYP2D6 genotype* -2.18% 0.576
CYP3A4 rs355367 genotype 1.51% 0.713
CYP3A5 rs776746 genotype 3.67% 0.361
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Figure 11. Factors associating with post-operative oxycodone requirement. NRS = 




5.7 Post-operative oxycodone and metabolite concentrations
Oxycodone and metabolite concentrations were available from 938 patients at the 
first	 state	 of	 adequate	 analgesia	 and	 from	 539	 patients	 at	 the	 time	 they	 required	
additional oxycodone. Forty-seven patients did not require oxycodone in the PACU, 
so their oxycodone concentrations were not determined and further15 patients, 
oxycodone concentration analyses were unsuccessful. 
Oxycodone	dose	and	plasma	concentrations	correlated	significantly	 (r=	0.599)	
as did the plasma oxycodone and metabolite concentrations at the two time 
points	 (Study	 I).	At	 the	first	 state	 of	 adequate	 analgesia,	 the	mean	oxycodone	
concentration was 41.3 ng/ml (Table 17). The concentrations of the metabolites 
of oxycodone were found to be relatively low at the initial measuring point and 
satisfactory oxycodone plasma concentrations was found to vary greatly between 
individuals. 
Table 17. Oxycodone and metabolite concentrations at the two measurement points.
At the first state of adequate  
analgesia






Oxycodone 41.3 (27.4) 33.3 (66%) 0 – 311
Noroxycodone 2.73 (2.93) 1.46 (106%) 0 - 16.5
Oxymorphone 0.146 (0.207) 0.11 (110%) 0 - 1.2
Noroxymorphone 0.392 (0.720) 0.26 (150%) 0 - 7.6
When patients needed a new  
dose of oxycodone
Oxycodone 26.7 (18.3) 21.7 (69%) 0 – 191
Noroxycodone 4.84 (3.57) 3.67 (73%) 0.2 - 19.3
Oxymorphone 0.186 (0.192) 0.14 (89%) 0 - 1.5
Noroxymorphone 0.967 (0.929) 0.67 (92%) 0 - 6.7
Patient’s motion pain intensity and type of surgery in the axilla were seen to 
associate with the oxycodone concentration needed for adequate analgesia (Study 
I). Each motion pain NRS score increased satisfactory post-operative oxycodone 
concentration by 21.7%. Axillary clearance increased satisfactory oxycodone 
concentration by 23.4% when compared to sentinel node biopsy. OPRM1, CYP3A4/5 
or CYP2D6	genotypes	did	not	show	any	significant	association	with	post-operative	
oxycodone concentration. 
CYP2D6 genotype associated with oxymorphone and noroxymorphone concentrations 
at the two measuring points (Study I) (Figure 12). As expected, patients with PM 
genotype showed minimal concentrations, whilst the highest concentrations were 
seen in patients with UM genotype. In all CYP2D6 genotype groups, the metabolite 
concentration remained low compared to oxycodone. 
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Figure 12. Oxycodone and metabolite concentrations by CYP2D6 genotype at the two 
measuring points. PM = poor metabolizer, IM = intermediate metabolizer, EM = extensive 






Ethical questions are particularly relevant when studying pain especially as pain 
cannot be assessed in study subjects unless they are exposed to some form of pain. 
The ethical guidelines of The International Association for the Study of Pain state: 
“In any pain research, stimuli should never exceed a subject's tolerance limit 
and subjects should be able to escape or terminate a painful stimulus at will. The 
minimal intensity of noxious stimulus necessary to achieve goals of the study should 
be established and not exceeded.” and “In all circumstances, including studies that 
employ placebo and sham treatment methods, an effective, accepted method of 
pain relief must be provided on request of the patient or subject. The availability of 
alternative pain relief should be made clear in the consent form and the instruction 
before the study begins.”
Our study was approved by two ethics committees of the Helsinki and Uusimaa 
Hospital District (HU: the Coordinating Ethics Committee and the Ethics Committee 
of the Department of Surgery). All patients volunteered to participate in the study 
and	gave	written	 informed	consent.	The	pain	 inflicted	 to	 the	patients	during	cold	
and heat pain testing was not harmful, the stimulus was of short duration and the 
patient could terminate the stimulation whenever they chose. In addition, the type 
of surgery was selected in relation to tumour characteristics, existence of malignant 
cells in the sentinel node and the patients’ wishes. All patients received standardised 
anaesthesia but, if the patient’s status so required, the protocol was violated to treat 
the patient in the best way possible. Moreover, patients whose surgery or anaesthesia 
had to be changed were excluded from the study. Post-operatively, all patients were 
titrated to satisfactory analgesia and all patients under study were not subjected to 
any	additional	pain	or	 suffering	when	compared	with	 similar	patients	undergoing	
surgery for breast cancer. On the contrary, they were monitored exceptionally well 
since all study patients were treated by their own anaesthesia nurse. 
6.1.2 The study cohort
The study sample of 1,000 women is large when compared with previous studies 
that	 have	 investigated	 the	 factors	 affecting	 post-operative	 pain	 and	 analgesia	 and	
exceptionally	 substantial	 compared	 with	 those	 focusing	 on	 the	 effect	 of	 specific	
diScUSSion
63
genes on these phenotypes. As Table 3 shows, most of the studies that have focused 
on OPRM1 and post-operative opioid requirement have been conducted with less 
than 300 patients. Nevertheless, when considering the multidimensional aspects of 
pain, an even larger study sample would be required to examine in more detail the 
individual	factors	affecting	pain	sensation	and	their	magnitudes.	The	multitude	of	
confounding factors regarding pain make it a hard phenomenon to study.
To	 our	 knowledge,	 this	 study	 is	 the	 first	 to	 address	 the	 effect	 of	FAAH on post-
operative	pain	intensity	and	oxycodone	requirements.	Kim	et	al	first	demonstrated	
the association between FAAH polymorphisms and cold pain in a relatively large 
sample of 735 individuals, however, their study population contained higher levels 
of ethnic variation (Kim et al., 2006).
In contrast, the current study patients were a relatively homogenous group - all patients 
were female and the vast majority of them were of Finnish origin (992 women). 
The	surgical	procedures	 included	 in	 the	study	consisted	of	 four	different	 types	of	
surgery: In the breast area, either conserving surgery or mastectomy was conducted, 
whereas in the axilla all patients underwent sentinel node biopsy. If malignant cells 
were	identified	in	the	sentinel	node,	axillary	clearance	was	performed	to	remove	all	
lymph nodes to eradicate cancerous cells. As a result, the confounding factors in this 
study were determined to be minimal. The kidney and liver functions of the patients 
were not analysed. Both could have provided important information considering the 
metabolism and clearance of oxycodone. 
6.1.3 The study procedure and genotyping
All study patients underwent the test in the same order: The day before surgery, all 
demographic and psychological data were collected and experimental cold and heat 
pain tests conducted. Furthermore, the anaesthesia protocol used was standardized 
for all patients. In the PACU, all patients were tested for both rest and motion pain 
before any oxycodone was administered. Nevertheless, it should be noted that the 
time patients required in order to reach satisfactory anaesthesia varied from 11 
minutes	 to	132	minutes	which	could	have	affected	 the	oxycodone	and	metabolite	
concentrations. Similarly, the duration of satisfactory analgesia varied from 10 
minutes to 18h. 
All genotyping was undertaken such that it as blind to patient phenotype. All 
genotypes were in Hardy-Weinberg equilibrium, which indicates that the study 
sample was large enough and there was no selective pressure on any of the alleles 
studied. Thus the results are comparable with other populations.
In our study the analgesic oxycodone concentration was based on the patients’ 
own report of satisfactory analgesia, which still is the most accurate measurement 
of	 pain	 intensity.	 However,	 many	 confounding	 factors	 known	 to	 affect	 the	
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experience	 of	 pain	 and	 analgesic	 requirement	 might	 have	 affected	 the	 results.	
The research nurse asked about the pain every 5 minutes instead of the patient 
reporting the exact time she reached satisfactory analgesia. Once the patient 
indicated satisfactory analgesia, no further oxycodone was administered until she 
indicated needing a new dose of oxycodone. Analgesic oxycodone concentrations 
varied extensively as did the concentrations at which the patients needed more 
oxycodone. The great interindividual variation in the analgesic concentration 
observed in this study is further evidence for the importance of personalized post-
operative	analgesia.	It	must	also	be	noted	that	the	adverse	effects	of	oxycodone,	
such as nausea and delirium, can occur already at concentrations that are below 
the analgesic concentrations. 
6.1.4 Statistical analysis and statistic and clinical significance
Studies	II	and	III	were	sufficiently	powered	-	excluding	one	rare	FAAH SNP - which 
ensures	that	the	study	sample	was	of	appropriate	size	to	observe	the	expected	effect	
sizes. Nonetheless, power calculations are always based on many assumptions, 
which increases the risk for misrepresentations in conclusions. The most common 
error	 is	 an	 overestimation	 of	 effect	 size	 that	 leads	 to	 an	 underestimation	 of	 the	
study	population	size.	This,	in	turn,	could	lead	to	a	failure	in	the	identification	of	an	
association and thus a false conclusion. All genotype-phenotype associations were 
conservatively corrected for multiple testing in order to minimise the probability of 
coincidental association. 
Statistical	 significance	 was	 set	 at	 corrected	 p-value	 <0.05,	 while	 results	 with	
uncorrected	p-value	<0.05	were	considered	nominally	 significant.	Furthermore,	 it	
has	 to	be	 acknowledged	 that	 statistically	 significant	 results	 do	not	 -	 necessarily	 -	
imply	that	the	results	are	significant	in	the	clinical	context.	
6.2 Factors explaining experimental pain intensities
In the linear regression model conducted in this thesis work anxiety level, age 
and FAAH rs324420	 genotype	were	 shown	 to	 significantly	 explain	 the	 perceived	
experimental cold pain intensity. Age reduced the reported pain intensity on average 
by 0.48% for every year, whereas anxiety and rs324420 G-allele increased the 
perceived pain intensity by 0.46% per STAI score and 8.4% for each G-allele. 
Together these factors explained 3.8% of the total variance between study patients.
Age has previously been associated with reduced post-operative pain intensity, but 
studies focusing on experimental pain intensities are few. Kim et al investigated cold 
and heat pain intensity with a population of 617 individuals aged between 16 to 66 




cold pain intensity in our study, it is likely that the association could be missed in 
studies with a smaller study population or less extensive age range.
Anxious individuals report higher pain intensities and pay more attention to painful 
stimuli (Eccleston et al., 1999; Keogh et al., 2002). Studies have shown that anxiety 
can increase the reported intensity of cold pain (Al Absi et al., 1991; Jones et al., 
2002) and in both studies anxiety was provoked prior to the cold pressor test. fMRI 
imaging showed that pain related anxiety can increase perceived pain intensity and 
that this activates the entorhinal cortex of the hippocampal formation (Ploghaus 
et al., 2001). In a study by Schidt et al., panic disorder patients reported higher 
anxiety sensitivity before a cold pressor test and both higher pain and anxiety 
intensities during the test than healthy controls (Schmidt et al. 1999). In this thesis, 
anxiety was associated with higher experimental cold pain intensities even though 
the majority of the patients had low anxiety according to the STAI scores (Kaunisto 
et al., 2013).
FAAH rs324420 genotype also associated with cold pain intensity with the minor 
allele homozygotes reporting the lowest intensities. Four FAAH SNPs showed either 
nominal	(uncorrected	p	<0.05)	or	significant	(corrected	p	<0.05)	associations	with	
cold	 pain	 in	 Study	 II.	 The	 two	 SNPs	 that	 produced	 significant	 association	 were	
rs324420 and rs1571138 and these two SNPs were shown to be in almost complete 
linkage disequilibrium. The SNPs producing nominal associations in the GWA 
analysis were rs3766246 and rs4660928 and these associations did not survive 
correction for multiple testing.
In a previous study by Kim et al., rs324420 did not show any association with cold 
pain,	 although	 the	 same	 study	 found	 significant	 associations	 between	 cold	 pain	
intensity and three SNPs (rs932816, rs4141964, rs2295633). Based on our own 
preliminary	targeted	SNP	analysis,	rs4141964	also	showed	significant	associations	
with cold pain intensity, heat pain intensity and oxycodone consumption. 
Unfortunately, the SNP was not found in the GWA data and so it was not included 
in the GWA analysis. 
All SNPs found to associate with cold pain (rs324420, rs4141964, rs3766426 and 
rs4660928) are located within 6 kb of each other. Rs324420 and rs3766426 were 
shown to be in 64% linkage disequilibrium as well as rs324420 and rs4660928 
(Study III). Rs4141964 was not included in this analysis due to its unavailability in 
the GWA data. Nevertheless, rs4141964 and rs324420 have been shown to locate 
in the same haploblock in a study by Bidwell et al. (2013). Therefore, any of these 
SNPs or some other SNP in strong linkage disequilibrium with them could cause 
the association signal. The fact that rs324420 causes an amino acid change makes it 
the most likely SNP to cause these associations, however, the impact of this variant 
on	 the	 protein	 configuration	has	 not	 been	 fully	 verified.	Chiang	 et	 al.	 (2004)	 did	
determine that in rs324420 A/A individuals the FAAH expression in T lymphocytes 
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was reduced to less than 50% compared with wild-type individuals. The reduction 
in	expression	was	shown	not	to	be	cell-type	specific.	When	transcription/translation	
efficiencies	were	compared,	the	change	in	expression	seemed	to	be	due	to	deficient	
post-translational folding of the protein, which led to cellular destabilization of the 
enzyme	(Chiang	et	al.,	2004).	Other	possible	explanatory	 factors	 for	 the	different	
expression levels include alternative splicing.
Reduced FAAH expression could lead to increased anandamide concentrations in 
the synaptic cleft, which in turn would lead to increased activation of the CB1 and 
CB2 receptors. However, as anandamide is only a weak agonist for the CB1 receptor 
compared with 2-AG, the magnitude of change in total CB1 activations remains 
uncertain. Moreover, as anandamide also has another metabolic pathway through 
COX-2, any change in the anandamide concentration in the synaptic cleft is a sum of 
the changes in these pathways. 
In this work, OPRM1 SNPs did not associate with either heat or cold pain intensities 
or cold pain withdrawal, even though weak association signals were determined for 
(uncorrected 0.01 <p> 0.05) of rs3778153 and rs4870266 with heat pain. Previously 
OPRM1 rs1799971 has been associated with cold and heat pain thresholds in a 
paediatric population where G-allele carriers presented with higher thresholds for 
both	heat	and	cold	pain	(Matic	et	al.,	2016).	In	another	study	that	focused	on	the	effect	
of the gene polymorphism on multiple experimental pain models, no association 
between OPRM1 SNPs and cold or heat pain was seen - Rs1799971 was included in 
the analysis (Nielsen, 2016).
6.3 Factors affecting post-operative pain intensity
In	 the	 linear	 regression	model	conducted	 in	 this	 thesis,	 the	 factors	affecting	post-
operative motion pain intensity were age, type of axillary surgery (SNB vs. AC), 
cold pain intensity at 30s and total time the patients kept their hand immersed 
in the cold water. Neither OPRM1 nor FAAH genotypes associated with post-
operative motion pain intensity. Post-operative rest and motion pain intensities 
correlated almost completely (r= 0.99). A previous descriptive study from our cohort 
reported	age,	 type	of	surgery	and	heat	pain	intensity	as	significant	factors	for	this	
same	phenotype	(Kaunisto	et	al.,	2013).	There	were	some	differences	between	the	
statistical methodology and tested variables between these two studies, which may 
explain why cold pain intensity and tolerance replaced heat pain intensity in this 
analysis.	The	effect	of	heat	pain	in	the	descriptive	study	was	relatively	weak	when	
compared with the associations of age and type of surgery. 
There are several previous studies where older age has been associated with lower 
reported post-operative pain intensities (Ip, 2009) and although numerous factors 
have	been	hypothesized	to	cause	this	phenomenon,	thus	far	no	definitive	explanation	




shown e.g. by Gerbershagen et al. (2013). In our study, the type of axillary surgery 
proved	to	be	a	significant	factor	associated	with	acute	postoperative	pain	intensity,	
while	the	type	of	surgery	in	the	breast	area	did	not	show	any	significant	association.	
Axillary clearance is performed when cancerous cells are found in the sentinel lymph 
node and the procedure aims to decrease the risk for cancer reoccurrence in the axilla 
and metastases. Nevertheless, the removal of lymph nodes in the axilla requires major 
surgery in an area highly innervated with nerves (Henry et al., 2017). Furthermore, 
the axilla also presents a high number of anatomical variations that make surgery 
more	difficult	and	subject	patients	to	complications	such	as	vascular	and	nerve	injury	
(Khan et al., 2012). Axillary clearance has been associated with higher occurrence 
of post-operative chronic pain and the development of lymphedema in the arm distal 
from the operation site (Göker et al., 2013; Bruce et al., 2014; Miguel et al., 2001). 
To	the	best	of	our	knowledge,	there	are	no	previous	studies	that	address	the	effect	of	
axillary clearance on acute post-operative pain intensity.
Both noxious cold stimulation and nociceptive pain induced by tissue damage 
during surgery activate the spinothalamic and spinoreticular tracts in the spinal cord. 
The spinothalamic route is hypothesized to function as the major pathway for the 
discriminatory-sensory	 component	 of	 pain,	 while	 there	 is	 evidence	 of	 affective-
motivational and pain modulating activities as well. The spinoreticular tract is 
also	 hypothesized	 to	 participate	 in	 the	 motivational-affective	 component	 of	 pain	
(Millan 1999). In the brain, cold pain has been shown to activate medial and lateral 
thalamus, parieto-insular cortex, anterior cingulate cortex and primary and secondary 
somatosentory cortex (Maihöfner et al., 2002; Boivie et al., 1989; Greenspan et 
al., 1999; Schmahmann et al., 1992; Davis et al., 1999; Craig et al., 2000; Craig et 
al., 1996; Davis et al., 1998; Casey et al., 1996). Injury-related nociceptive pain, 
such as post-operative pain, has been demonstrated to activate PAG, hypothalamus, 
prefrontal cortex, insula, anterior cingulate cortex, posterior parietal cortex, primary 
somatosensory and motor cortexes, supplementary motor area and cerebellum 
(Hsieh et al., 1996).
It has been hypothesized that experimental cold pain intensity could correlate and 
therefore predict post-operative pain intensity. So far, the studies that have investigated 
this correlation have produced mixed results: In two small studies (20 and 54 patients), 
cold pain showed no correlation with post-operative pain (Lautenbacher et al., 2009; 
Martinez	et	al.,	2007).	In	contrast,	Bisgaard	et	al.	did	find	a	significant	association	
between cold pain tolerance and post-operative pain intensity when they studied 150 
patients undergoing cholecystectomy (Bisgaard et al., 2001). This could indicate that 
to identify association between cold pain and post-operative pain requires a large 
study	sample	for	the	test	results	to	reach	statistical	significance.	In	our	study,	each	
cold pain intensity NRS score raised the post-operative NRS score by 1.8% and each 
second of cold pain tolerance by 0.13%. 
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6.4 Factors affecting the oxycodone dose required for 
satisfactory analgesia
In the analysis performed as part of this thesis, the factors associated with post-
operative oxycodone dose required for satisfactory analgesia were post-operative 
motion pain intensity, BMI, type of surgery in the axilla, OPRM1 rs1799971 genotype, 
age and preoperative breast pain during the week prior to surgery. Together these 
factors explained almost 29% of the interpatient variation in oxycodone requirement, 
however, a proper therapeutic range for oxycodone could not be determined since 
both the oxycodone doses and concentrations varied substantially. 
The major predictor for post-operative oxycodone requirement was post-operative 
motion pain intensity with every NRS point increasing the required oxycodone dose 
by 23.1%. This indicated that post-operative pain intensity could be used as a clinical 
sign that predicts part of the oxycodone dose required for satisfactory analgesia. In 
addition, those patients who reported the highest pain intensities also required the 
largest doses of post-operative oxycodone. This knowledge can be used to titrate 
patients to adequate analgesia faster.
The patient related factors associating with the required oxycodone dose were age, 
BMI and OPRM1 rs1799971 genotype. Older age and BMI associated with lower 
doses of oxycodone, whilst OPRM1 rs1799971 GG-homozygotes required on 
average 0.04 mg/kg more than A-allele carriers did. 
The negative correlation between age and analgesic consumption has been noticed in 
many	studies	and	in	a	review	that	investigated	the	factors	affecting	post-operative	pain	
intensity and analgesic consumption (Ip et al., 2009). Of the eight studies included, six 
found associations with age and analgesic consumption, while two studies presented 
conflicting	results.	The	reduced	opioid	requirement	has	been	hypothesized	to	be	due	
to reduced metabolism and excretion of opioids (Liukas et al., 2011). Furthermore, as 
elderly	people	also	have	on	average	less	lean	body	mass	this	could	affect	the	distribution	
of oxycodone in the body. Oxycodone resembles morphine in being less lipophilic than 
fentanyl and buprenorphine (Pöyhiä et al., 1994). 
OPRM1 rs1799971 genotype was shown to be associated with post-operative 
oxycodone dose requirement in both Study II and in the stepwise linear regression 
(Table	16.)	The	putative	effect	of	OPRM1 rs1799971 could be due to the altered half-
life and endorphin binding potential of the mutated receptor. The mutated receptor 
is less stable when compared with the wild-type receptor (Huang et al., 2012). As 
discovered	by	Bond	et	al.,	it	binds	β-endorphin	3	times	more	effectively	than	the	wild	
type	receptor	(Bond	et	al.,	1998).	Therefore,	the	overall	effect	of	OPRM1 rs1799971 
is	offset	by	 the	reduced	expression	of	 the	receptor	and	 the	higher	binding	affinity	




dynorphin showed no changes in receptor binding. Oxycodone was not tested (Bond 
et al., 1998).
The OPRM1 rs1799971 G-allele has been shown to increase post-operative opioid 
requirements in three previous large studies (Tan et al., 2009, Sia et al., 2013, Sia et 
al., 2008), whereas in smaller studies, the results have been inconclusive. Only two 
prior	studies	(266	and	48	patients)	have	assessed	the	effect	of	OPRM1 rs1799971 on 
oxycodone requirements and both found no association (Zwisler at al., 2012, Bruehl 
at	al.,	2006).	A	possible	explanation	for	the	conflicting	results	might	be	the	alternative	
splicing	and	epigenetics	which	confound	the	effect	on	OPRM1	rs1799971	(Oertel	
et al., 2012). In our Study II, the patients who were homozygous for the G-allele 
required - on average - 0.16 mg/kg of oxycodone, while AA individuals required 
0.12mg/kg and AG individuals 0.13mg/kg.
Axillary clearance was associated with higher oxycodone requirements as well as 
higher post-operative motion pain intensities. However, as motion pain intensity was 
also an independent factor associated with post-operative oxycodone requirement, 
axillary	clearance	has	an	indirect	effect	on	oxycodone	dose	requirement.	
Previously, preoperative pain has been associated both with post-operative pain 
intensity and post-operative analgesic consumption (Ip et al., 2009). In our study, 
preoperative breast pain during the week before surgery associated with post-
operative oxycodone requirement but not with post-operative motion pain intensity. 
Surprisingly, anxiety did not associate with either post-operative pain intensity or 
analgesia requirement, even though previously anxiety has been shown to associate 
with higher post-operative intensities and analgesic requirements. Opioids, including 
oxycodone,	have	anxiolytic	effects,	which	could	lead	to	anxious	patients	demanding	
higher doses to suppress anxiety. Generally, our patients reported quite low anxiety 
scores,	which	could	explain	why	anxiety	did	not	show	any	significant	associations	to	
post-operative outcomes (Kaunisto et al. 2013). 
6.5 Oxycodone and metabolite concentrations 
The factors that associated with post-operative oxycodone plasma concentration 
required for satisfactory analgesia were post-operative motion pain intensity and 
type of surgery in the axilla (Study I). 
The analgesic oxycodone concentrations varied remarkably. The oxycodone dose 
and concentration correlated highly but not completely (R2= 0.599, Study I). Even 
with the same oxycodone dose, the analgesic concentration varied up to fourfold and 
as such, no general analgesic concentration could be determined.
The other factors (BMI, Age, OPRM1 genotype and preoperative breast pain) 
associated with the oxycodone dose required for satisfactory analgesia did not show 
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any association with nalgesic oxycodone concentrations. The lack of association of 
age and BMI could indicate that the oxycodone given stayed in the plasma and did 
not absorb to other tissues (excluding the CSF). In general, elderly people have a 
reduced total blood volume (Messerli et al., 1983), which could explain the higher 
concentrations received with smaller doses. High BMI caused by excess body fat 




and noroxymorphone at both studied measurement points. Patients with the UM 
genotype showed over three times higher oxymorphone concentrations when 
compared to the patients with PM genotype at both measurement points. Oxymorphone 
has	been	 shown	 to	have	a	high	affinity	 to	 the	mu-opioid	 receptor	 (Lalovic	 et	 al.,	
2006), therefore, the increased metabolite formation associated with CYP2D6 
UM-genotype could reduce the analgesic oxycodone requirement. Nevertheless, 
the	CYP2D6	genotype	did	not	affect	the	oxycodone	dose	or	plasma	concentration	
required for satisfactory analgesia, which could be due the low concentration of 
oxymorphone even in CYP2D6 ultra-rapid metabolizers (Study I) and partly to 
the	differences	 in	BBB	penetration.	To	our	knowledge,	no	human	data	 exists	but	
with mice the CSF concentration of oxycodone has been shown to be twice as high 
compared to plasma concentration 60 minutes after dosing. For oxymorphone the 





pain sensitivity and post-operative analgesics requirements. Better knowledge of 
these	factors	would	offer	important	tools	for	clinicians	to	predict	the	patients’	post-
operative pain intensity and opioid requirement. Especially data of the estimated 
effects	of	the	statistically	significant	explanatory	factors	is	valuable	information	for	
clinicians who treat post-operative pain. Even though this study was able to identify 
several	 significant	 explanatoryfactors	 for	 each	 of	 the	 studied	 pain	 variables,	 the	
coefficient	 of	 determination	 (i.e. the proportion of the variance in the dependent 
variable that is predictable from the independent variable) for each of the regression 
models	was	quite	low.	As	a	result,	there	has	to	be	other,	still	yet	unidentified	clinical,	
demographic	and/or	genetic	factors	that	affect	the	investigated	phenotypes.	It	is	likely	
that even larger sample sizes of high quality are required to identify these factors.
Development of personalized medicine is one of the major goals for the 21st century 
and in order to achieve such individualized treatment a massive amount of genomic 
diScUSSion
71




of this variance is very likely due to genetic factors. The next major step would 
be	 to	 perform	 a	GWAS	with	 sufficient	 study	 sample,	 unified	 surgical	 procedures	
and a replication material, however production of high quality GWAS requires huge 
resources and collaboration of multiple research centres. 
This	 study	 also	 provided	 evidence	 of	 FAAH’s	 effect	 on	 cold	 pain	 intensity.	
Unfortunately,	 no	 significant	 association	 with	 any	 of	 the	 studied	 post-operative	
phenotypes were noticed. The results indicate that at least common variation within 
the FAAH gene is not a major player in modulating post-operative pain and analgesia. 
This	finding	could	prove	to	be	valuable	information	when	considering	the	growing	




Conclusions addressing the aims of this thesis:
I. Post-operative pain intensities and analgesic concentrations of oxycodone 
showed	significant	interindividual	variation.
II.	 The	most	 important	 factor	 affecting	 post-operative	 oxycodone	 requirement	
after breast cancer surgery was post-operative pain intensity. The magnitude 
of	 this	 effect	was	 significant	 both	 statistically	 and	 clinically.	 Other	 factors	
associated with post-operative oxycodone dose requirements were type 
of surgery, BMI, age, OPRM1 rs1799971 genotype and the intensity of 
preoperative pain.
III.	 The	major	factors	affecting	post-operative	pain	 intensity	after	breast	cancer	
surgery	were	 age	 and	 type	 of	 surgery.	The	magnitude	 of	 these	 effects	was	
significant	both	statistically	and	clinically.	Results	of	 the	experimental	pain	
tests	 performed	 before	 the	 surgery	 –	 specifically	 cold	 pain	 intensity	 and	
tolerance – showed a weak correlation with post-operative pain intensity, but 
due	 to	 the	 low	 level	 of	 this	 effect,	 the	 correlation	was	 regarded	 as	 having	
minor	clinical	significance.
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